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ABSTRACT 
Adult multipotent stromal cells (MSCs) in combination with biocompatible scaffolds may 
augment well-established medical and surgical techniques.  Pre-implantation cell loading and 
viability on scaffold carriers followed by in vitro differentiation and extracellular matrix 
(ECM) formation contribute to the efficacy of in vivo tissue formation.  Given the specificity 
of the parameters for each cell-scaffold construct, it is vital to assess the relative potential of 
various combinations to select the best option for various clinical needs.  High demand for 
equine and human bone regeneration especially non-union fracture repair is still largely 
unaddressed.  Therefore osteogenesis potential of both equine and human MSCs engrafted on 
bioscaffolds was comprehensively investigated in this study.  After loading onto scaffolds, 
cells attached to scaffolds were assessed immediately and following different time of culture.  
Cell number, viability, distribution and differentiation were evaluated with DNA levels, 
confocal laser, light, and scanning electron microscopy (SEM) and RT-PCR.  Both perfusion 
bioreactor and spinner flasks loading proved to be reliable and efficient procedures for 
seeding cells within bioscaffolds as well as achieving uniform cell distribution.  Tissue 
specific micro- and ultrastructural changes were evident in equine cell-scaffold constructs 
cultured in induction medium.  The versatility and suitability of type I collagen (COLI) 
scaffolds for equine adult MSC tissue regeneration was confirmed by generation of distinct 
mesenchymal tissues by paired adipose- (ASCs) and bone marrow derived multipotent 
stromal cells (BMSCs).  In vivo study of equine MSCs on COLI scaffold further supported 
bone formation by BMSC constructs after short-term induction.  However, ASC constructs 
produced comparative ECM as that of BMSC constructs but under commitment into dermal-
like tissue.  Pre-induction times as well as osteoinductive biomaterial addition to ColI 
xii 
 
scaffold were optimized to improve efficiency of human ASCs constructs to commit 
osteogenesis.  The customized bioscaffold was proved in vitro as a promising carrier of 
MSCs to meet diverse clinical needs for osteogenesis.  Overall, this research established 
straightforward and reproducible procedures to support customized tissue engineering with 
bioreactor loading of MSCs onto proper scaffolds. This achievement extensively supports 
customized equine tissue engineering to meet various clinical needs of equine bone 
regeneration in the near future. 
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CHAPTER 1. STEM CELL RESEARCH FOR REGENERATIVE MEDICINE: 
PRINCIPLES AND METHODOLOGIES 
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1.1 The Past Overview, Present Perspective and Future Challenges  
In 2001, President Bush imposed boundaries on embryonic stem cell research because of the 
debated ethical issues.  This caused limited research funding attributed to stem cell research.  
Since President Barack Obama lifted restrictions on federal funding for stem cell research in 
2009, the previous policy that had restrained the development of stem cell research has been 
reversed. With recent advancement in the clinical application of stem cell research and the 
rapidly increased demand of stem cell application in clinics, an effort has been made to 
combine stem cell research with tissue engineering methods to broaden its prospective in 
regenerative medicine.   
1.1.1 Major Stem Cell Research Breakthrough in Last Two Decades 
From perspective of clinical value, the history of stem cells dates back to 1896, when E. 
Goujon showed that autologous marrow induces bone at heterotopic sites.  A Keith 
conducted a classic experiment in 1919 revealing osteogenic activity from marrow, which 
was further confirmed by RG Burwell in 1961. The fact that multipotent stromal cells (MSCs) 
can be isolated from adult whole marrow was first proposed and proved later by AJ 
Friedenstein [1].  The importance of MSCs was further established by their key role in 
supporting hematopoietic cell proliferation in vitro [2] and transplantation in vivo [3].  Stem 
cells isolated from mouse embryos have the ability to proliferate indefinitely while 
maintaining pluripotency [4-5].  With the finding of MSCs and investigation of their 
behavior, bone marrow was applied for treating non-union bone fractures [6].  Bone marrow 
application was also found to provide cells for chondrogenesis and promote articular 
cartilage healing process.  The milestone of this field was successful isolation of stem cell 
from human embryos [7].  Pluripotent stem cells were successfully cultured a few days later 
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from germ cells [8].  The research on stem cells has moved forward at rapid speed 
subsequently.  Human embryonic stem cells were found to be capable of dedifferentiating 
into myeloid precursurs by cell-cell fusion [9], which provides a model for investigation of 
nuclear reprogramming. The factors that induced this reprogramming were unveiled by 
groundbreaking work from Shinya Yamanaka when he identified a few defined factors 
(Oct3/4, Sox2, c-Myc and Klf4) crucial to cell stemness.  He confirmed this finding by 
introducing these factors into fibroblasts, which successfully produced induced pluripotent 
stem (iPS) cells [10].  iPS cells, which displayed the essential characteristics of embryonic 
stem cells, were successfully produced one year later by introducing four factors (Oct4, Sox2, 
NANOG and Lin28) into human somatic cells [11].  A total of 13 lines embryonic stem cells 
were approved by US regulators for use in scientific research in 2009.  Food and Drug 
Administration approved the study using embryonic stem cell research to treat human spinal 
cord injuries in 2010.  It did not take long to apply this research accomplishment in clinics. 
On October 2010, the first patient with a spinal cord injury was treated in a U.S.-government-
approved study by receiving millions of human embryonic stem cells.  
1.2 Multipotent Stromal Cells Characteristics 
1.2.1 Definition of Adult Multipotent Stromal Cell 
Adult stromal cells represent a heterogeneous population. For example, only an estimated of 
1 in 10,000 or 15,000 cells in bone marrow are marrow derived MSCs (BMSCs) [12].  
BMSCs along with other stromal cells dispersed in tissues throughout the mature animal are 
referred to adult stromal cells in general.  Adult stromal cells have the common 
characteristics as all stromal cells: self-renewal and differentiation. Cells divide into identical 
copies of themselves and maintain their differentiation capacity for a long period of time. For 
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example, equine MSCs proliferated for up to 30 passages before senescence in vitro [13].  
Their ability to differentiate is a two-step process. Normally adult stromal cells give rise to 
intermediate cell types called precursors or progenitor cells.  Later, these partially 
differentiated precursors or progenitor cells divide and give rise to specific differentiated 
cells.  Although these two common characteristics of adult stromal cells are acknowledged 
worldwide, the definition of adult stromal cells is expanded into many levels with updated 
discovery in this field.  To characterize adult stromal cells, more strict criteria have been set 
besides spindle cell morphology and cell capacity of differentiation [14].  
1.2.2 Adult Stromal Cell Plasticity 
Adult stromal cells from one tissue type have the capacity to differentiate into different tissue 
specific cell types. This is frequently referred to as “plasticity”, “transdifferentiation” or 
“unorthodox differentiation”.  Various studies have demonstrated that adult stromal cells are 
capable of producing cell types besides the cell type in the tissue of origin under certain 
microenvironmental conditions.  BMSCs give rise not only to skeletal muscle cells [15-16] 
and cardiac muscle cells [17-18] but also to liver cells [19-20], which are from the different 
mesoderm derivative. Furthermore, BMSCs can differentiate into neural tissue, which arises 
from the ectoderm germ layer [21-22].  Interestingly, adult brain tissue derived neural 
stromal cells could differentiate into hematopoietic cells [23].  The most possible reason 
might be heterogeneous populations of cells and co-infusion of multiple different stromal 
cells.  Therefore for specific stromal cell plasticity research, it is established that stromal cells 
should be purified to ensure only one cell type is used and it should be labeled as well to 
track the stromal cells behavior and evaluate their engraftment into their new tissue 
environment.  
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1.2.3 Adult Stromal Cell Niches 
The stromal cell niche and its interaction with stromal cells is an essential research topic in 
multipotent stromal cells biology. To date, majority of studies on adult stromal cell are 
conducted in vitro.  Normally stromal cell niches cannot be reconstructed in vitro.  Therefore 
adult stromal cell self-renewal and multipotentiality cannot be maintained for a long period 
of culture outside of the orignial niches in most cases.  The complex molecular interplay of 
stromal cells and their niches has been intensely investigated so that artificial niches can be 
reconstructed in vitro.   
Stromal cell niches are defined as a 3-D complex and controlled microenvironment that 
physically hosts the stromal cells in an anatomically well-defined location within a tissue[24]. 
Stromal cells are surrounded by extracellular matrix (ECM), growth factors, cytokines and 
other cells that provide a complex mixture of extrinsic cues. A variety of interactions are 
included: 1) cell-cell interactions such as cadherins, cell adhesion molecules and notch 
ligands; 2) ECM adhesion such as fibronectin, laminin, collagens and proteoglycan; 3) 
metabolic cues such as ions, hormones; 4) biophysical aspects such as physical forces, 
substrate elasticity and spatial arrangement; 5) soluble signals such as growth factors, 
cytokines and chemokines. 
There are several proposed mechanisms for stromal cell niches [25].  Development of 
effective method is still in progress to identify niche cells from other specific cell types. 
These questions need to be addressed to inspire the application of stromal cell niche in vitro 
and eventually promote tissue regeneration in clinics.  Tissue engineering plays an important 
role on providing robust spatial and temporal control of biophysical and biochemical 
microenvironmental cues for adult stromal cell to maintain their multipotentiality. 
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Bioscaffolds, as temporary structural supports for directing cell growth, create powerful 
artificial microenvironments to regulate cell function to promote tissue regeneration and 
repairs [26].  Secreted ECM surrounding cells on bioscaffolds is capable of attracting 
cytokines, growth factors and nearby progenitor cells to accelerate tissue regeneration.  
Optimization of cell-bioscaffolds interactions promise to have a profound impact on adult 
stromal cell biology and provide insights that will advance adult stromal cell-based clinical 
approaches to tissue regeneration.   
1.2.4 Multipotent Stromal Cell Homing 
The capacity of MSCs in tissue regeneration depends largely on its migration to injury sites. 
The homing of leukocytes is directed by various chemokine receptors, ligands and adhesion 
molecules, which also stimulated trafficking of hematopoietic precursors into and through 
tissue [27].  Adhesion molecules, such as selectins, β1-integrins and their respective 
counterligands, play an important role in mediating contacts between microvascular 
endothelial cells and blood leukocytes [28].  Then integrin activation is triggered by 
chemokines presented on endothelial cells.  The leukocytes that carry the corresponding 
receptors are arrested by corresponding chemokines as well.  The adherent leukocytes move 
across the endothelial cell and then get access into the injured tissue.  
Similar to leukocytes, MSCs is capable of migration into tissues from the circulation in 
response to upregulated signals under injury conditions.  It is possible that the similar group 
of adhesion molecules, chemokines and their receptors are involved.  Overall, there are a 
variety of chemokine receptors that play an important role in MSCs trafficking.  For example, 
stromal cell-derived factor-1 (SDF-1) and its receptor have been reported to assist migration 
of certain progenitor cells and homing of hematopoietic stromal cells, respectively.  Research 
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on SDF-1 has proved its therapeutic potential in tissue regeneration [29].  In response to 
injuries, cells with highly expressed SDF-1 caused increased SDF-1 levels at damaged sites.  
This leads to recruitment and retention of circulating progenitor cells.  For tissue engineering 
applications, corporation of SDF-1 protein into scaffolds improved the regeneration of the 
damaged tissue or organ [29].  
1.2.5 Multipotent Stromal Cell Immunophenotyping 
The immunophenotyping of adult stromal cells has recently become very popular for the 
purpose of identifying the presence and proportions of the various cell populations of interest. 
Flow cytometry is preferred because of its single cell based accuracy and multiple efficient 
measurements to characterize the specific antigens expressed on cells.  Research has been 
conducted to characterize specific stromal cell population and thus achieve the goal of 
accurate cell sorting.  
The following antibodies have been previously validated as specific markers for their 
respective molecules in human and horses.  CD29, also known as integrin beta 1, has diverse 
roles in several biological processes including cell migration during development and wound 
healing, cell differentiation, and apoptosis by mediating interactions between adhesion 
molecules on adjacent cells or the extracellular matrix.  CD 44 is a cell-surface glycoprotein 
involved in cell-cell interactions, cell adhesion and migration as well.  It is a receptor for 
hyaluronic acid (HA) and also interacts with other ligands, such as osteopontin, collagens, 
and matrix metalloproteinases (MMPs).  CD73, known as ecto-5’-nucleotidase, is largely 
expressed on the vascular endothelium and is useful for lymphocyte adhesion and 
differentiation.  CD90, known as Thy-1 membrane glycoprotein, is considered as a 
fundamental regulator in cell-cell and cell-matrix interactions, with important roles in nerve 
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regeneration, metastasis, inflammation, and fibrosis.  CD105, known as an endoglin, 
participates in cell adhesion and embryonic angiogenesis expressed in vascular endothelial 
cells and some bone marrow cells and activated macrophages. Both CD34 and CD45 are 
considered as common hematopoietic cell surface markers.    
It has been found that the phenotype of the culture-expanded MSCs was similar for all fetal 
tissues (bone marrow, liver, lung, and spleen), i.e. CD90, CD105, CD166, SH3, SH4 and 
HLA-ABC positive and CD34, CD45 and HLA-DR negative [30].  Rat MSCs have been 
tested to be CD11b-, CD45-, CD29+, CD49e+, CD73+, CD90+, CD105+ and Stro-1+ [31].  
In human, MSC from bone marrow, umbilical cord and placenta were positive for 
multipotent cell marker (CD29, CD44, CD105, CD73 and CD90) [32]. Equine BMSCs had 
shown to be negative for CD45 and CD34, and positive for CD44, CD29 and CD172a [33].  
It has been shown that cell immunophenotype varies not only based on the specific stromal 
cell type but also in response to passage changes. For example, MSCs are identified by a 
CD45- and CD106+ phenotype normally. However, mouse MSCs achieve this characteristic 
phenotype only at later passages. With increasing passages, CD45 expression shifted to 
negativity, whereas CD106 expression became increasingly positive [34].  Because cell 
population becomes more homogenous after passages but its multipotentiality may decrease 
over time.  Therefore optimal cell passage should be chosen based on the profile of its cell 
surface marker.  
1.2.6 Isolation and Culture of Multipotent Stromal Cells 
MSCs isolation and expansion techniques are vital to substantial progress in MSCs 
application in clinical trials of tissue regeneration.  The low isolation rate, slow MSCs 
proliferation and low differentiation rate is partly attributable to suboptimal isolation and 
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expansion conditions.  There are several influential factors that will be discussed, including 
oxygen level, cell plating density, substrate used for cell isolation and culture as well as 
mechanical forces applied on cells.  Among these, oxygen level and mechanical stimulation 
can be controlled by bioreactors to provide a suitable environment for cell growth to promote 
tissue regeneration.  
1.2.6.1 Oxygen 
The physiology of MSCs is affected by the oxygen level in many aspects, including cell 
attachment, growth, differentiation and tissue regeneration capability [35].   MSCs respond 
differently to hypoxia condition in vivo and in vitro. It is important to characterize their 
behavior in order to acquire optimal in vitro culture and successful in vivo implantation by 
adjusting oxygen level [36].    
Because hypoxic conditioning modulates MSCs paracrine activity, activates signaling 
pathways that control cell cycle rates and upregulate various important genes that increase 
their migratory phenotypes [35, 37]. In cell culture, hypoxia results in increased cell 
proliferation rates and cell migration. Furthermore, hypoxia enhanced cell differentiation 
along different mesenchymal lineages. It contributed to adipogenesis of human MSCs 
without affecting PPAR-gamma2 maturation pathway [38].  A previous study on rat MSCs 
showed that hypoxic conditioning had beneficial effects on chondrogenesis [39].  In order to 
adapt to low oxygen tension in vivo, MSCs were pretreated with hypoxic environment, which 
avoided massive hypoxia-induced cell death after implantation [36]. Hypoxic pretreatment 
was also considered as an effective way to overcome hypoxia-induced inhibition on 
osteogenic differentiation in vivo [40].  
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Although the effects of hypoxia have not been well established, the current achievement in 
finding its role in cell survival, proliferation and differentiation provides us the guidance for 
its application in tissue engineering.  Proliferation rates of MSCs can be increased and its 
multipotency towards different mesenchymal lineages can be enhanced under hypoxia 
condition, which could potentially decrease the time needed for cell expansion and induction 
in vitro. Long-term cell survival in vivo could be achieved by hypoxic preconditioning of 
MSCs.  Perfusion bioreactors can provide cells with controlled oxygen level.  It has been 
shown that perfusion bioreactors in the culture environment of 30% O2 level improved cell 
adhesion and expansion in contrast to those in 5% O2 where expansion rate was 3 times 
lower.  Bioreactors provided controlled O2 conditions to promote efficient cell productions 
[41]. 
1.2.6.2 Mechanical Stimulation 
Cells are surrounded by a highly complex biomechanical environment in vivo.  Unveiling the 
mechanical effects on cells in vivo could inspire the design of bioreactors and thus provide 
suitable environments for cell growth in vitro.  In general, mechanical conditioning has the 
potential to stimulate cell growth and tissue formation.  But there exist wide variations for the 
effects of mechanical conditioning among different cell types and different mechanical forces 
may exert different effects as well. It is vital to establish the effects of specific mechanical 
forces on the specific tissue formation. Thus optimized bioreactors can be tailored to meet 
the needs of specific cell type.  
Osteocytes, the most mechanosensitive cell type in bone [42-44], are active in bone adaption 
to mechanical stimulation.  Signaling molecules such as nitric oxide (NO) and prostaglandins 
are produced in response to shear stress stimulation exerted by fluid flow, which play 
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important roles in the change of functional and structural properties of bone adapted to 
mechanical load in vivo [45-46].  Rapid increases in prostaglandin production induce fully 
differentiated bone cells in vitro [43, 47-48]. Evaluation of osteopontin (OPN) and collagen 
type Iα1 (COL1A1) expression is a common tool to assess bone cell mechanoresponsiveness 
[49-51]. This established mechanism of bone cell response to mechanical forces provides a 
tool to investigate responses of BMSCs and ASCs to mechanical conditioning [52].  The 
mechanosensitivity of BMSCs and ASCs indicate their potential for musculoskeletal tissue 
engineering.  
1.3 Bioscaffolds 
Scaffolds play a significant role in regenerative medicine by creating a structural 
environment to support cellular interactions and new tissue formation.  Scaffold selections 
take into consideration the biodegradability and biocompatibility properties, which are 
determined by the material composition.  Researchers must further modify the porosity and 
pore size of scaffolds to improve nutrient transfer and cell adhesion capacity.  This is key to 
successfully decreasing the possibility of necrotic center formation.  The challenge of 
scaffold design, however, is to improve a scaffold’s porosity and pore size without 
compromising its mechanical properties.   
1.3.1 Biomaterial  
To present, scaffolds used in tissue regeneration can be categorized into three main types: 
ceramics, natural and synthetic polymers.  To meet a variety of clinical needs, copolymers 
(made up with different polymers) and composite scaffolds (made up with both ceramics and 
polymers) are introduced to combine desired properties from different biomaterials.  
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1.3.1.1 Ceramics 
The two main components of ceramics are β-tricalcium phosphate (β-TCP) and 
hydroxyapatite (HA).  The chemical composition for β-TCP and HA is Ca3(PO4)2 and 
Ca10(PO4)6(OH)2, respectively.  Biocompatibility of β-TCP and HA makes it an excellent 
candidate for osteoinductive scaffolds because of their resemblance to bone inorganic 
component. These scaffolds provide osteoconductivity as well and may bind directly to bone 
to support bone ingrowth [53-55].  Previous studies have unveiled that calcium phosphates 
support the attachment, differentiation and proliferation of osteoprogenitor cells [56].  But 
the low mechanical strength limits their direct application in bone regeneration, especially at 
load-bearing positions. 
Bioactive glass is currently regarded as the most biocompatible material in the bone 
regeneration field because of its excellent bioactivity, osteoconductivity and osteoinductivity 
[57].  This material, which shows direct bonding to living bone, is likely to open the door to 
the development of new nanostructured bone regeneration materials.  Moreover, this scaffold 
can accelerate osteoconduction in bone defects with coated bone-like apatite on the surface 
[58].   
1.3.1.2 Natural Polymers 
The common natural polymers are collagen and silk.  Collagen, a major component of ECM, 
has the advantage of biocompatibility, biodegradability and efficient cell capture for tissue 
repair. In previous studies, collagen/hyaluronate matrix demonstrated high biocompatibility 
and osteoconductivity in treating cranial defects in rats [59].  Tibia rat defects implanted with 
collagen scaffolds presented a low inflammatory response and bone formation within a short 
period of time [60].  Collagen is considered a promising choice for bone regeneration 
 13 
 
because of the low cost of production associated to the biocompatibility and 
osteoconductivity. In addition to its osteoconductivity, collagen scaffold has also been used 
for mice dermal regeneration because it supports cell infiltration and vascularization [61].  
However, collagen scaffolds also have low biomechanical properties and relatively high 
degradation rates, which excludes them from use in load-bearing sites [62]. To overcome 
these issues, chemical modification is introduced by cross-linking to decrease degradation 
rates and improve mechanical strength. Collagen scaffold, which was cross-linked by 
carboxyl-amine chemistry, demonstrated significantly decreased degradation rates compared 
with collagen scaffold [63].   
Another alternative to collagen scaffolds are silk-based scaffolds. This idea was originally 
inspired by long-term use of silk as suture material because of its biocompatibility as well as 
excellent mechanical properties [64-67].  Porous silk scaffold can be produced by dissolving 
the silk fibroin produced after lyophilizing the aqueous silk solution [68]. Previous studies 
showed similar degradation rates between silk-based scaffolds and cross-linked collagen 
constructs [63].  Human BMSCs proliferate and differentiate on silk scaffolds [69] and form 
trabecular-like structures under static culture conditions [70].  Moreover, osteogenesis on silk 
scaffolds could be improved by increasing its pore size [71].   
1.3.1.3 Synthetic Polymers  
The customized scaffolds for different tissues are required with the rapid development of 
tissue engineering. Synthetic polymers provide diversity by altering fabrication parameters 
such as changing monomeric units, their connectivity and microstructure.  The morphology 
and porosities as well as pore sizes can be modified to match tissue specific needs for 
mechanical properties and rates of degradation. Increase in porosities allows for adequate 
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diffusion but it should be adjusted without compromising its mechanical properties.  
Saturated poly-α-hydroxy esters, such as poly-l-(lactic acid) (PLLA), poly-(glycolic acid) 
(PGA) and poly-(lactic-co-glycolide) (PLGA), polyethylene glycol (PEG) are considered 
among the most biodegradable synthetic polymers for 3D scaffolds and have wide 
applications in tissue engineering.   
Because of their porous tubular structures, PLGA and PLLA scaffolds have promising 
potential for tubular tissue regeneration like blood vessels, peripheral nerves, intestines and 
long bone [72].  Previous study have also shown that fabricated PLGA with an 
interconnected porosity was capable of promoting tissue in-growth in teeth [73].  For in vitro 
culture, scaffolds with the multi-pore sizes and the 2-layer provided more efficient nutrient 
and oxygen exchange environments for cell culture. With this advantage, synthetic polymers 
promoted more efficient human dermal fibroblast cells proliferation significantly compared 
with uniform-pore size scaffold [74]. 
In the other studies, synthetic polymers were coupled with peptide to improve human 
osteoprogenitor cells adhesion, migration, expansion and differentiation to promote new bone 
formation [75]. Furthermore, better bone ingrowth into the scaffold and bone formation was 
shown in skull defects of rabbits by PLGA/polyvinyl alcohol blended scaffold compared with 
PLGA only scaffold [76].  In addition to chemical modifications, extracellular biomaterials 
can also be introduced to scaffolds to promote cell attachment and proliferation.  PLGA 
scaffolds mixed with porcine ECM recruited a significantly larger number of BMSCs that 
contributed to the subcutaneous implant site remodeling [77].  
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 In addition to chemical modifications, physical modifications were introduced as well to 
change geometry of a scaffold and thus verify its regulations of cell activities.  Early studies 
on a PGA scaffold made of 13 µm microfibers demonstrated highly effective chondrogenesis 
based on morphology and composition of its constructs seeded with chondrocytes [78].  
PLLA scaffolds composed of nanofibers and seeded with chondrocytes promoted more 
efficient cartilage regeneration compared with that of microfibers [79].  Nanofibrous PLLA 
scaffolds were also loaded with human BMSCs to accelerate cartilage regeneration in clinics.  
Compared with autologous cartilage grafts, cell-scaffold constructs grew into better 
predefined dimensions and shape to repair cartilage defects [80].   
1.3.2 Scaffolds for Bone Regeneration  
In order to find a compatible scaffold for bone regeneration, the material composite of bone 
should be considered.  Bone consists of two parts, the inorganic part and the organic part. 
The inorganic component is mainly calcium and other mineral salts. Calcium is present in the 
form of hydroxyapatite with composition Ca10(PO4)6(OH)2.  About 60% to 70% of the dry 
weight is made by these minerals.  The organic part is comprised of type I collagen and 
ground substance. The ground substance, primarily formed by proteoglycans, is 
interconnected with mineralized collagen fiber, and thus develops into extracellular 
matrix[81].  This explains why majority highly investigated scaffolds have these two 
components.   
1.3.2.1 Osteogenesis, Osteoinductivity and Osteoconductivity 
These three properties of implants, osteoconductivity, osteoinductivity and osteogenesis, are 
essential to the success of bone healing.  Osteogenesis means that there are viable cells from 
implants that contribute to the new bone formation. Cytokines, growth factors, hormones are 
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transferred by implants to modulate host cells, which is osteoinductivity.  The matrix 
provided by implants supports new bone formation that is perpetuated by the native bone, 
which is called osteoconductivity.  
1.4 Bioreactor Designed for Tissue Engineering   
The uses of equine stromal cells to address equine tissue regeneration needs have become 
increasingly popular over the last decade. However, no current applications of equine stromal 
cells include cell seeding, culture and differentiation on a scaffold inside of a bioreactor[82]. 
In order to establish a protocol for efficient in vitro tissue regeneration by equine stromal cell, 
a custom tailored bioreactor should be designed. There are three established types of 
bioreactors.  The three types of bioreactors will be described here are spinner flask, perfusion 
bioreactors and rotating wall vessel (RWV) bioreactors. 
1.4.1 Bioreactor Components and Assembly 
Spinner flasks are cost effective, easy to operate and fit scaffolds with different sizes. 
Additionally, using spinner flasks can increase the mixing of oxygen and nutrients 
throughout the medium during cell culture compared with static culture.  One spinner flask 
can accommodate higher number of scaffolds compared with other two bioreactors.  All the 
scaffolds within the same spinner flask are provided with the identical loading condition. 
However, spinner flasks certainly have limitations that other dynamic cell cultures do not 
have. A needle is applied through the neural axis of scaffold for fixation during loading. 
Therefore, this will affect the integrity of subsequent tissue formation given the center of 
scaffold including a hole penetrated by the needle.  Moreover, the amount of time required 
for seeding is longer and the cell seeding efficiency is lower at low cell concentrations 
compared with other dynamic systems [83]. In addition, spinner flask culture causes non-
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uniform distribution of cells [84] with a higher density of cells on the scaffold surface[83].  
The turbulence generated by stirred medium causes tissue disintegration by releasing newly 
formed matrix in medium[85]. If it is gently stirred, the mechanical stress generated may not 
be sufficient to induce differentiation [86-87]. 
Perfusion bioreactor shows higher seeding efficiency, more uniform cell distribution [84] in a 
relative short loading time compared to the other two bioreactors. Its capability of both 
seeding and culture could minimize the chance of contamination [88-89].  This bioreactor 
can also enhance matrix deposition because of its adjustable flow rate to balance between the 
nutrition transfer and the waste disposal as well as to balance between the growth of matrix 
and the fluid shear stress [35].  Compared to spinner flasks, the perfusion bioreactor is more 
expensive, more time-consuming for assemble and requires adjustments periodically. 
Additionally, perfusion bioreactors cannot avoid cell aggregates forming within scaffolds 
because cell seeding and culture is still in 2-dimensional (2D) space without any diffusional 
flow at horizontal direction. There will be a necrotic center in the cell aggregate. For stromal 
cell differentiation, there is enhanced osteogenesis supported by BMSCs [90-92].  Compared 
with static loading on starch-based polymer scaffold, more homogeneous bone graft with 
better quality was achieved by perfusion bioreactor loading [93]. 
RWV bioreactor has higher mass transfer rate because of dynamic laminar flow to reduce 
diffusional limitations and exerts low shear stress [83]. Cells are naturally gathered, which is 
called cell apposition, without forming cell aggregates. Close cell apposition provides 
optimum distance among cells and allows normal cell-cell interactions, which promote cell 
proliferation and differentiation via specialized cell adhesion molecules and autocrine or 
paracrine cell signaling [86-87]. In addition, RWV bioreactors can develop a spatially 
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extended ECM because they provide 3-dimensional (3D) communications for both cells and 
scaffolds [94]. In conclusion, among these three bioreactors, RWV bioreactor provides 
controlled microenvironment more analogous to natural cells and tissues. It has been shown 
that RWV bioreactors promote osteogenesis of stromal cell.  The condition of RWV 
bioreactors should be optimized based on different requirements for differentiation [95]. 
1.4.2 Requirement for Bioreactor Designs 
The first and most important step of 3D stromal cell culture is cell seeding and it is crucial in 
determining the progression of subsequent tissue formation. For clinical application, there 
would be less amount of biopsy required for tissue collection and less time needed for cell 
expansion if high cell seeding efficiency can be achieved.  Higher seeding enhances tissue 
formation by increasing the number of cells attached to scaffolds. The initial distribution of 
cells in the scaffold after seeding determines the distribution of the subsequent tissue 
formation. Uniform cell seeding could facilitate uniform tissue generation. Therefore, to 
compare the advantages and limitations of these three bioreactors, efficiency and uniformity 
of cell seeding are important factors to be considered. Stromal cell differentiation is mainly 
determined by mechanical stimulation controlled by bioreactors [95-96]. There are 
established studies on mechanical stimulation to induce ligament regeneration from MSCs 
[97], which displays the possibility of achieving multipotentiality or pluripotentiality of 
stromal cell in vitro by controlled bioreactors and lays the ground for tissue repair through 
regeneration medicine. 
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1.5 Applications 
1.5.1 Adipogenesis 
The fact that BMSCs and ASCs can both show adipogenesis potential is not only used to 
confirm the multipotentiality of BMSCs and ASCs but also have potential applications for 
clinical uses.  In human medicine, there is a wide range of adipose tissue applications such as 
in treating burns, avulsions, lipodystrophy, post-surgical defects and so on. In equine 
medicine, the applications are limited due to fewer uses in these problems for horses and thus 
they are still largely unexplored. Because of the capacity of BMSCs and ASCs differentiation 
into adipocytes and the similar cell types, it is highly anticipated that BMSCs and ASCs 
transplantation would promote wound healing. It has been shown that BMSCs played a 
significant role in treating wound healing in rats [98-99].  In addition, adipocytes carry out 
important endocrine functions and can be produced by BMSCs and ASCs to meet different 
endocrine needs.  
1.5.2 Chondrogenesis 
Up to date, there is a continuous demand for seeking effective remedy for cartilage repair in 
equine medicine.  Horses are at high risk of getting focal articular cartilage injuries especially 
for sporting horses.  A lot of surgical techniques have been developed to promote cartilage 
regenerations. For example, cell transplantation using autogenous or allogenous 
chondrocytes is used frequently to support healing over the past decade [100-106].  However, 
because of the inner environment of cartilage, it is normally isolated from circulation and 
thus the repair is not effective especially for adults.  The chondrogenic capacity of BMSCs 
and ASCs provides a more effective alternative to promote repair. Currently a lot of cartilage 
repair stimulated by adult MSCs implant have been successfully conducted in rats [107], 
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rabbit [108-109], dog[110] and goat[111].  These studies showed promising results. The 
study of using this method for cartilage repair conducted in equine showed that the BMSCs 
implantation accelerated healing in a short term, proving it as a straightforward, cost-
effective and clinically effective approach for cartilage repair[33, 112-113]. 
1.5.3 Osteogenesis 
Although the surgical and medical techniques for bone repair are well established in human 
medicine, there is still a largely unmet need for efficient, quick and satisfactory bone healings 
to accommodate the variety of patient conditions such as non-union fracture, congenital cleft 
palate, lesions caused by removing bone cancer, periodontal disorders and injuries associated 
with a severe car accident.  Acute bone injuries are common for athletic horses. If they 
cannot be addressed efficiently in time, horses may develop degenerative disease and 
lameness. High demand for equine efficient bone regeneration is still largely unmet.  
 Both autograft and allograft are applied to provide fine alternatives for bone repairs.  
However, their limitations should be taken into considerations. Autograft is quantitatively 
limited and has risks in causing morbidity, pain and possible infection of the donor site. 
Allograft could cause immune rejection and disease transmissions[55, 107, 114]. Therefore, 
current methods for bone grafts should be optimized on osteogenesis of MSC alone or with 
them engrafted on the biocompatible scaffolds suitable for bone generations.   
It has been shown that bone healing of rat with a femoral segmental defect was facilitated 
with MSCs derived from bone marrow[107].  MSCs with a high aldehyde dehydrogenase 
activity showed efficient fracture healing with a short period of time[114].  In equine patient, 
cells mediated with osteoinductive gene promoted the rib drill defects by increased bone 
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filling volume and mineral density[115].  However, long-term risks of viral vectors need to 
be taken into considerations such as immune and inflammatory responses, toxicity and 
potential risk for wrong DNA integration.  Pre-induced adult equine MSCs seeded on 
bioscaffolds can provide a promising alternative for bone repairs.   
The cell-scaffold constructs have been applied to produce inductive bone graft both in vitro 
and in vivo.  BMSCs loaded onto biophasic calcium phosphate scaffolds by perfusion 
bioreactors system produced clinically relevant and viable amount of tissue-engineered bone 
after implantation in nude mice[116].  BMSCs and ASCs loaded on mineralized collagen 
sponges showed new bone formation at a critical size defect on the sheep tibia[117].  
Therefore engineered bone constructs can provide a customized and potentially permanent 
cure of specific bone injuries in equine medicine.         
1.6 Applications in Equine Veterinary Medicine  
Injection of MSCs isolated from bone marrow aspirates, adipose tissue or umbilical blood 
into lesions is most commonly used in equine clinics.  This technique is referred to as equine 
stem cell therapy. Stem cell therapy is considered as a simple, one-step, autogenously, and 
arthroscopically applicable treatment.  Equine adult MSCs has potential to restore normal 
tissue structure and function. This is shown not only by in vitro laboratory work but also by a 
large number of clinical cases treated successfully by current stem cell therapy with fast 
recovery rate and low rate of reinjures compared to other therapy.  Full thickness cartilage 
defects have been successfully treated with BMSCs injection [33].  Majority of MSC therapy 
applied to treat orthopedic lesions are frequently used to accelerate tendon and ligament 
repair.   
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However, current stem cell therapy certainly has some limitations to impede its further 
development.  It still takes time for the healing to take effect.  For some conditions especially 
acute injuries, if it cannot be addressed efficiently, horse may develop degenerative disease 
and lameness. High demand for equine bone regeneration is still largely unmet.  How stem 
cell therapy works is not completely understood and the treatment was applied mainly based 
on empirical data.  For example, there is uncertainty of exact dose and frequency of the 
treatment to repair different injuries.  More research is required to learn how and why stem 
cell therapy work in a certain way and to investigate how to employ MSCs to optimize its 
ability to heal a particularly tissue in order to reach their full potential. The wide availability 
of multiple cell sources and bioscaffolds provides more alternatives for clinician to consider, 
and may augment well-established medical and surgical techniques. But optimization of their 
interactions is still largely undone in equine medicine.  Solid evidence-based research is 
necessary to evaluate their interactions in vitro as the first critical step, to promote its 
application for the best possible cell growth, differentiation and subsequent in vivo function.  
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2.1 Introduction 
Adult equine multipotent stromal cell (MSC) research supports their potential to restore 
normal tissue structure and function.  The use of adult equine MSCs to address equine tissue 
regeneration needs is a promising research focus [118-130].  Use of adult equine MSCs in 
combination with biocompatible scaffolds may augment established medical and surgical 
techniques.  To derive the most benefit from clinical equine MSC applications and propel the 
technology into clinical trials, it is necessary to optimize interactions between the cells and 
biocompatible scaffold carriers in vitro for the best possible cell growth, differentiation and 
subsequent in vivo function.  
An appropriate scaffold, favorable environment and multipotent cell source are three major 
components of tissue engineering [82, 131-133].  Based on published information, cell 
growth and differentiation efficiency in vitro are different between adult equine BMSCs and 
ASCs [13, 134].  Biocompatible scaffolds are designed to support cell growth and extra 
cellular matrix formation for efficient tissue repair.  Given distinct differences between cells 
isolated from different equine stromal cell sources, scaffolds tailored to each type are critical 
to their application for tissue regeneration.  Some considerations in this regard include 
scaffold composition, stromal cell loading and pre-implantation culture. 
Cell seeding is one of the first processes of three-dimensional stromal cell-scaffold construct 
generation.  The use of a bioreactor for cell loading provides a well-defined, controlled 
environment, and bioreactors are key to successful stromal cell tissue regeneration [82, 122, 
133].  To date, bioreactors have not been used extensively with equine stromal cells [82].  
High cell seeding efficiency reduces the required initial cell number and thus decreases time 
consumed by cell expansion, which may interfere with timely implantation.  Cell distribution 
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in the scaffold affects subsequent tissue formation, and uniform cell seeding facilitates 
homogenous tissue generation [85].  Use of a perfusion bioreactor to load adult equine MSCs 
onto biocompatible scaffolds may have significant, positive effects on equine MSC tissue 
regeneration [84, 90-92, 135-138].  
Collagen scaffolds have advantages for tissue engineering like biocompatibility, 
biodegradability and high cell adhesion that have been demonstrated in a number of species 
[59-61, 139-142].  They also support efficient cell capture and growth, both critical to  tissue 
formation [143].  Collagen based scaffolds are used widely and have been applied for 
generation of bladder [144], bone [145], brain [146-147], cartilage [148-149], heart [143] and 
skin [150] tissue among others.  Therefore it is anticipated that collagen scaffold is suitable 
for multiple tissue regeneration.  However, a systematic and comprehensive in vitro 
evaluation of interactions between collagen scaffolds and equine MSCs is necessary to 
evaluate their potential to support diverse mesenchymal tissue production.    
The overall goal of this study was to investigate adult equine MSC interactions with collagen 
type I (COLI) scaffolds for purposes of advancing clinical application of equine tissue 
regeneration technology.  Several hypotheses were tested to support this aim.  The first 
hypothesis was that equine BMSCs and ASCs have indistinguishable cell seeding, 
attachment, viability, and distribution on COLI scaffolds.  The second hypothesis was that 
BMSC – COLI and ASC – COLI scaffold constructs have comparable capability for three 
major specific tissue formation: adipogenesis, osteogenesis and chondrogenesis.  To test 
these hypotheses, adult equine ASC and BMSC seeding efficiency, viability and distribution 
on collagen scaffolds was quantified immediately after perfusion bioreactor loading.  
Additionally, adipogenesis, osteogenesis, and chondrogenesis of ASC- and BMSC-COLI 
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constructs were compared to each other and uninduced controls with micro- and 
ultrastructure analysis as well as mRNA levels of tissue specific target genes after loading 
and following 7, 14, and 21 days of culture.   
2.2 Materials and Method 
2.2.1 Experimental Design 
Cell passage 0 or 1 paired equine ASC and BMSCs were thawed from cryopreservation and 
expanded to P3.  Cells (106 cells/scaffold) were loaded onto 10 x 7 x 3 mm bovine corium 
collagen type I scaffolds (Davol Inc, Cranston, RI) by perfusion bioreactor.  A total of 37 
scaffolds were seeded with each cell type per animal (296 scaffolds/total).  From each animal, 
one scaffold was used to evaluate cell viability and distribution directly after loading.  Two 
construct for each medium, culture period, and animal was used to evaluate cell viability and 
distribution by confocal laser microscopy and microstructure by light microscopy (one 
construct each), and two were used to isolate DNA and RNA to determine cell proliferation 
and mRNA level, respectively.  Additional MSC-constructs were cultured for 21 days in the 
three induction medium for scanning electron microscopy (SEM) ultra-structural analysis. 
2.2.2 Animals 
Tissue harvest procedures were reviewed and approved by LSU Institutional Animal Care 
and Use Committee prior to the initiation of the study.  Cells were harvested from 4 
Thoroughbred geldings (7 to 10 years).  Bone marrow (BM) was collected from sternebrae 
and subcutaneous adipose tissue was collected superficial to the gluteal muscle fascia as 
previously described [13, 134]. Stromal cell isolation was performed immediately after tissue 
harvest.   
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2.2.3 Stromal Cell Isolation 
The BM aspirate was diluted 1:1 with stromal medium consisting of DMEM-Ham’s F12 
(Hyclone, Logan, UT) with 1% antibiotic/antimycotic solution (MP Biomedical, Irvine, CA) 
and 10% characterized fetal bovine serum (FBS, [Hyclone, Logan, UT]), layered over Ficoll-
Paque PLUS (Stem Cell Technologies, Vancouver, BC Canada) and centrifuged (350g, 30 
min).  Total nucleated cell number per unit volume BM aspirate was calculated for each 
sample [134]. 
Adipose tissue was minced in a sterile petri dish, washed, briefly agitated with an equal 
volume of phosphate buffered saline (PBS), and then allowed to separate into two phases.  
The infranatant was digested in an equal volume of PBS containing 1% bovine serum 
albumin type V (BSA, [Sigma, St Louis, MO]) and 0.1% collagenase type I (Worthington, 
Lakewood, NJ).  The mixture was continuously rotated at 370C for 30 minutes with brief 
agitation every 15 minutes.  The stromal-vascular fraction (SVF) pellet was then isolated by 
centrifugation (350g, 5 min) and suspended in 2 ml of stromal medium.  A small aliquot of 
the cell suspension was centrifuged and resuspended in an equal volume of red cell lysis 
buffer for 5 minutes.  The total nucleated cell number per unit volume of adipose tissue was 
calculated [134]. 
2.2.4 Cryopreservation 
Passage 0 or 1 cells from each horse were cryopreserved in aliquots of 1 x 106 cells/ml in 
cryopreservation medium (80% FBS, 10% DMEM, and 10% dimethylsulfoxide). 
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2.2.5 Flow Cytometry 
Freshly revitalized cells were cultured for 4-5 days to approximately 70% confluence.  Cell 
aliquots (2 x 105/ul PBS) were incubated individually with each of the following PE or FITC 
conjugated antibodies CD 34, CD29，CD73, CD44, CD45, CD90 and CD105 (Table 1) for 
30 minutes in room temperature.  Autofluorescence was measured with cell aliquots without 
antibody.  Samples were rinsed with PBS followed by centrifugation (350g, 5 minutes).  Cell 
pellets were fixed in 30 ul of cold 1% formalin prior to FACS analysis.  
2.2.6 Cell Seeding 
Following revitalization, cells were expanded to P3 (70-80% confluence prior to passage) in 
stromal medium.  Cells in stromal medium were loaded onto 7 x 10 x 3 mm bovine corium 
collagen I scaffolds in a perfusion bioreactor.  The perfusion bioreactor has been previously 
described [151] (Figure. 1).  Briefly, scaffolds were placed into custom-designed perfusion 
cartridges and held in place by rubber gaskets.  Cells suspended in culture medium passed 
only through the area occupied by scaffolds.  Two perfusion cartridges were connected at 
their dependent ends by a 13 cm length of 0.48 cm diameter tygon tubing attached with luer 
connectors.  There was a side tubing with 28 cm length and 0.31 cm diameter attached 
vertically on the top of each cartridge by three way stopcocks (Smiths Medical Asd Medex).  
The system was closed by two filters (0.22 µm, Millipore, Billerica, MA) connected to side 
tubings to maintain sterility during the seeding process.  Each system of two cartridges was 
loaded with 5 ml of stromal medium.  A cell suspension (1 x 106 cell/scaffold) ASCs or 
BMSCs in 2 ml stromal medium) was added to the system through injection ports on one of 
the three way stopcocks.  The perfusion system was connected to a peristaltic pump via pump 
tubings (Ismatec, Glattbrugg, Switzerland).  The perfusion direction and flow rate were 
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controlled by a customized program (Labview, National Instrument, USA).  Loading was 
performed for two hours in a humidified incubator (37º C, 5% CO2) at a flow rate of 1.05 
ml/min.  The direction of fluid flow was reversed after the lowest level of the medium 
reached the top of a cartridge to ensure scaffolds immersed in the medium during loading. 
Table 1 Information,of antibodies for flow cytometry 
AB Label Manufacturer Marker Specification Antibody properties 
CD29 (1st) N/A BD Biosciences Integrin Beta 1, MSC Marker Mouse anti-canine 
IgG (2rd) FITC Sigma N/A Rabbit anti-mouse 
CD44 FITC eBioscience Cell-surface Glycoprotein, MSC Maker Mouse anti-canine 
CD73 FITC eBioscience 5’-Nucleotidase, MSCs Markers Mouse anti-human 
CD90 PE eBioscience Thy-1, MSC Marker Mouse anti-canine 
CD105 PE eBioscience Type I Glycoprotein, MSC Markers  Mouse anti-human 
CD34 PE BD Biosciences Cell adhesion, Hematopoietic cell marker Mouse anti-canine 
CD45 PE BD Biosciences Leukocyte, Hematopoetic cell marker Mouse anti-canine 
 
Figure 1 Perfusion bioreactor system for scaffold seeding. 
COLI scaffolds were placed inside a rubber gasket. Scaffolds in bioreactors were fixed 
by rubber gasket. Two bioreactors were assembled in one closed perfusion system. Cell 
suspension was injected into system through injection sites.  
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2.2.7 Induction Medium 
For adipogenesis, cell-scaffold constructs were cultured in adipogenic induction medium 
(DMEM-Ham’s F12, 3%FBS, 1% antibiotic/antimycotic solution, biotin [33 µmol/L], 
pantothenate [17 µmol/L], insulin [1 µmol/L], isobutylmethylxanthanine [0.5 mmol/L], 
dexamethasone [1 mM], and rosiglitazone [5 µmol/L]) for 6 days and then in adipogenic 
maintenance medium (induction medium without isobutylmethylxanthanine and 
rosiglitazone) until collection.  For chondrogenesis, cell-scaffold constructs were cultured in 
chondrogenesis medium (high glucose DMEM-Ham’s F12, 1%FBS, 1% 
antibiotic/antimycotic solution, transforming growth factor-β3 [10 ng/ml], dexamethasone 
[100 nm], ascorbate-2-phosphate [50 µg/ml], proline [40 µg/ml], sodium pyruvate [100 
µg/ml], and 1% ITS + Premix [BD Biosciences, Bedford, Mass; 6.25 µg/ml insulin, 6.25 
µg/ml transferrin, 6.25 ng/ml selenious acid, 1.25 mg/ml bovine serum albumin, and 5.35 
mg/ml linoleic acid]).  For osteogenesis, cell-scaffold constructs were cultured in osteogenic 
medium (DMEM-Ham’s F12, 20% FBS, 1% antibiotic/antimycotic solution, β-
glycerophosphate [10 µmol/L], dexamethasone [20 nmol/L], and sodium 2-phosphate 
ascorbate [50 µg/mL]).  
2.2.8 Loading Efficiency 
After removal of the scaffolds, the remaining medium was removed from the system, 
centrifuged (350g, 5 minutes), and the total number of cells was determined using a 
hemocytometer and light microscopy.  Subsequently, 4 ml of trypsinase (Hyclone, Logan, 
UT) was added to the system and manually distributed through the system for 5 minutes.  
The number of cells within the extracted trypsinase was determined as for the stromal 
medium.  Loading efficiency was calculated as follows: 
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Percent loading efficiency = 100% x [1 – (cell #medium + cell #trypsinase/Initial cell number)] 
Where cell #medium = total # of cell in the medium, cell #trypsinase = total # of cells in trypsinase.  
2.2.9 Cell Viability 
Cell viability was determined following incubation of cell－scaffold constructs with a 
live/dead stain containing calcein and ethidium bromide (EB) for 30 minutes according to the 
manufacturer’s instructions (Sigma, St Louis, MO).  Live cells stained green by metabolizing 
calcein AM and dead cells stained red by intercalation of EB into DNA double helix (Figure 
2).  Scaffolds were viewed at 10x using a confocal laser microscope equipped with argon and 
rhodamine filters (Leica TCS SP2, Buffalo Grove, IL).  A total of 20 sequential digital 
photomicrographs were generated every 1µm from one surface to the other in the perfusion 
plane of each scaffold.  Digital images were exported as JEPG images and evaluated using 
graphics software (Image-Pro, Media Cybernetics, Bethesda, MD).  Z plane images were 
assigned to regions; the 10 sections closest to each surface were defined as surface regions, 
and the 10 sections between the surface regions were defined as the center region.  The 
spatial uniformity ratio was calculated as follows:  Spatial uniformity ratio = % viable 
cellssurface/% viable cellscenter. 
2.2.10 Cell Numbers 
Cell-scaffold constructs were stored in TRI Reagent (Molecular Research Center, Cincinnati, 
OH) at -80。C after each culture period.  DNA was isolated from the interphase, washed and 
solubilized according to the manufacturer’s protocol.  Total DNA content was quantified 
using nanodrop reader (Nanodrop, Wilmington, DE).  .The cell number in each scaffold was 
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then determined from the total DNA content following generation of a standard curve from 
known numbers of MSCs. 
A. B.  
Figure 2 Live/dead cell stain on one sequential section of scaffold generated by confocal 
laser microscopy 
Green color introduced by calcein stain indicating live cells (A), and red color 
introduced by ethidium homodimer indicating dead cells (B). 
2.2.10 Light Microscopy 
Constructs were fixed in 4% neutral buffered formalin, embedded in paraffin and stained 
with Masson’s Trichrome (5 µm sections) for light microscopy (Leica DM 4500B, Allendale, 
NJ).  Constructs cultured in osteogenic medium were also stained with Von Kossa’s stain and 
those cultured in chondogenic medium with alcian blue.  Scaffolds cultured in stromal 
medium and scaffolds without cells were stained similarly for comparison. 
2.2.12 Scanning Electron Microscopy 
Cell-scaffold constructs cultured in stromal, adipogenic, osteogenic, or chondrogenic 
medium were evaluated with scanning electron microscope after 21 days of culture.  
Constructs were fixed in 2% paraformaldahyde and 1.25% glutaraldehyde in 0.1 M sodium 
cacodylate (CAC) buffer, pH 7.4.  Samples were rinsed in 0.1M CAC buffer with 5% sucrose 
and incubated with 1% osmium tetroxide in 0.1 M CAC buffer.  They were dehydrated in a 
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series of ethanol-distilled water solutions, critical point dried in a Polaron CO2 bomb, and 
then sputter coated with gold and palladium. Samples were imaged with a scanning electron 
microscope (Quanta 200, FEI Company, Hillsboro, OR) at 15 kVP.  
2.2.13 RT-PCR   
Constructs were stored in TRI Reagent at -80°C following culture.  Constructs were 
homogenized in tissue lyzer (Qiagen, Valencia, CA) and then RNA was isolated according to 
the manufacturer’s protocol.  After DNase treatment, RNA was reversely transcribed to 
cDNA using oligo dT and M-MLV reverse transcriptase (Sigma, St Louis, MO).  Real time 
polymerase chain reaction was performed using SYBR Green supermix (Bio-Rad, Hercules, 
CA) with ABI Prism 7900HT sequence detection system (Applied Biosystem, Foster City, 
CA).  Equine-specific primers for adipogenic (peroxisome proliferator-activated receptor 
gamma [PPARγ], lipoprotein lipase [LPL] and leptin), osteogenic (collagen type I [COLI], 
osteocalcin [OC], and alkaline phosphatase [ALP]) and chondrogenic lineages (collagen type 
II [COLII] and sex determining region Y- box 9 [Sox9]) were used for all analyses (Table 2).  
The housekeeping gene, Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH), was 
used to determine the ΔCT value for each gene of interest.   
2.2.14 Statistical Analysis 
All outcomes are reported as mean ± standard deviation (SD).  Student’s t test was performed 
to compare effects of cell type on loading efficiency.  Three-way ANOVA was used to 
determine effects of cell type, culture time and induction medium on cell viability.  Two-way 
ANOVA was used to compare the effects of cell type and culture time on mRNA expression 
levels.  Different combination effects were evaluated with Tukey’s post-hoc tests.  
Significance was considered at P<0.05.  
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Table 2 Equine-specific primers designed for RT-PCR  
Markers Genes Forward Primers Reverse Primers 
Stemness  Oct4 TCGTTGCGAATAGTCACTGC AGTGAGAGGCAACCTGGAGA 
 Nanog CCCAGCTCTGTGTCCTCAAT TTGCTAGTCTTCGGCCAGTT 
 Sox2 CAGCTCGCAGACCTACATGA TGGAGTGGGAGGAAGAGGTA 
Adipogenesis PPARγ AAGGAGAAGCTGTTGGCAGA GGTCAGTGGGAAGGACTTGA 
 Leptin GGCTTTGGCCCTATCTGTTC ACCAGTGACCCTCTGTTTGG 
 LPL GAGGACACTTGCCACCTCAT TACCATTCCTGTCACCGTCCA 
Osteogenesis ColI CTGGAATGAAGGGACACAGAG ACCTCTCTCACCAGGCAGAC 
 ALP CGGGACTGGTACTCG GAC CATGTACTTCCGGCCGCC 
 Osteocalcin TGGCCCTGACTGCATTCTG CCCTCCTGCTTGGACATGAA 
Chondrogenesis Sox9 GGCAAGCAAAGGAGAAGAA CAGAGAGGCACAGGTGACAG 
 Aggrecan ACACGGATGGTGTCCTCTTC CTCAGTCCCACGGGTTACGAT 
 ColII ACTTTCCAATCCCAGTCACG GTCTGCCCAGTTCAGGTCTC 
2.3 Results 
2.3.1 Loading Efficiency 
The loading efficiencies, 74.6% ± 14.4% and 85.8% ± 9.2% for BMSCs and ASCs, 
respectively, were not significantly different between cell types.   
2.3.2 Flow Cytometry 
Stromal cell surface marker expression was higher in BMSCs for four out of five of those 
investigated in this study.  Specifically, 99.86% of BMSCs and 87.81% of ASCs were 
CD29+; 77.96% of BMSCs and 31.06% of ASCs were CD44+; 43.71% of BMSCs and 1.35% 
of ASCs were CD73+; 40.57% of BMSCs and 1.34% of ASCs were CD90+; and 79.27% of 
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BMSCs and 97.01% of ASCs were CD105+.  ASCs were negative for CD34 and CD45, but 
16% of BMSCs were positive for CD34 and 8% were positive for CD45 (Figure. 3).   
A.  
 
B.  
Figure 3 A). Histogram of flow cytometry results. B). Cell morphology of both cell types. 
A). Histogram of CD 29, CD44, CD73, CD90, and CD105 antibody stained cell (black) 
with auto fluorescent control cell (green) for both BMSCs and ASCs. B). BMSCs and 
ASCs morphology of P1 before flow cytometry taken by microscope at 10x.  
2.3.3 Cell Viability 
Immediately after loading, percentages of viable cells were similar between center and 
surface regions in all scaffolds.  There were no effects of cell type, culture time or medium  
BMSCs ASCs 
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A.                                   
B.1  2 C.1  2              
    3 4     3  4  
D. 1 2  E.   1 2              
3 4           3  4  
Figure 4 A). Mean±SD of spatial uniformity to evaluate BMSC viability on COLI 
scaffolds. B)-E). BMSCs morphology on scaffolds demonstrated by live/dead stain over 
time (1 – 0, 2 – 7, 3 – 14, 4 – 21 days) in adipo- (B), chondro- (C), osteogenic (D) and 
stromal medium (E).  
A). Spatial uniformity (mean±SD) of viable cells in BMSC constructs after 0, 7, 14, or 
21 days of culture in adipogenic, chondrogenic, osteogenic and stromal medium.  B)-E). 
BMSCs changed from round shape at 0 day immediately after loading to spindle shape 
after 14 days of culture when they started to form cell aggregates.  BMSCs appeared to 
be embedded in amorphous collagenous matrix after 21 days of induction. 
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A.                                   
B.1. 2  C. 1. 2              
    3. 4.       3.  4.  
D.1. 2.      E.1. 2.              
3.   4.          3.  4.  
Figure 5 A). Mean±SD of spatial uniformity to evaluate ASC viability on COLI 
scaffolds. B)-E). ASCs morphology on scaffolds demonstrated by live/dead stain over 
time (1 – 0, 2 – 7, 3 – 14, 4 – 21 days) in adipo- (B), chondro- (C), osteogenic (D) and 
stromal medium (E).  
A). Spatial uniformity (mean±SD) of viable cells in ASC constructs after 0, 7, 14, or 21 
days of culture in adipogenic, chondrogenic, osteogenic and stromal medium.  B)-E). 
ASCs changed from round shape at 0 day immediately after loading to spindle shape 
after 14 days of culture when they started to form cell aggregates.  ASCs appeared to be 
embedded in amorphous collagenous matrix after 21 days of induction. 
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on spatial uniformity ratios.  Notably, cells were round and distinct from each other 
immediately after loading.  After 14 days of culture, cells assumed a spindle shape and 
formed cell aggregates.  Cells appeared to be embedded in amorphous collagenous matrix 
after 21 days of induction (Figs. 4 and 5). 
2.3.4 Cell Number 
Overall, there were no significant differences between ASCs and BMSCs based on DNA 
content.  Cell number on the scaffolds for BMSCs was affected significantly both by culture 
time and medium type and for ASCs was significantly affected by medium type. There were 
significantly more cells in BMSC constructs cultured in chondrogenic medium than in 
adipogenic or stromal medium after 21 days of culture (Fig. 6).  The ASC constructs in 
stromal medium had significantly higher cell numbers than those in the three induction 
medium after 21 days.  ASC constructs had significantly more cells after 14 and 21 days of 
culture in stromal medium than after 7 days (Fig. 6). 
2.3.5 Light Microscopy 
Both ASC and BMSC constructs cultured for 21 days in induction medium tended to 
colonize the intrafibillar spaces of the scaffold and produce their own extracellular matrix 
(ECM) within formed cell aggregates compared with constructs in stromal medium (Fig. 7A-
H).  The BMSC constructs cultured in chondrogenic or osteogenic medium showed similar 
cellular morphology with clusters of heterogenous cell populations composed of round 
chondrocyte-like, polygonal osteoblast-like and undifferentiated longitudinal stromal cell-
like structures within ECM (Fig. 7B&C).   In constrast, ASC constructs cultured in 
chondrogenic or osteogenic media were showed distinct differences between chondro-
induced and osteo-induced types.  There were cell aggregates emmeshed in fibrous ECM in  
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Figure 6 Mean ± SD of relative cell number of both BMSCs and ASCs on collagen 
scaffold over time.  
Mean±SD of relative cell numbers of both BMSCs and ASCs on collagen scaffold over 
culture time (7, 14 and 21 days) in adipogenic, chondrogenic, osteogenic and stromal 
medium. * indicates significant differences at 14 and 21 days compared with 7 days. |---| 
indicates significant differences between groups with different medium at the same time 
points.  
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constructs cultured in chondrogenic medium, while those cultured in osteogenic medium 
tended to have all cell aggregates of polygonal osteoblast-like cells with less spindle and 
round shaped cells (Fig. 7 F&G).  ASC constructs cultured in adipogenic medium contained 
ellipsoid lipoblast-like cells containing lipid droplets while BMSC constructs contained 
sparse round cells that were smaller in size. 
Both tissue density and proteoglycan staining with alcian blue increased with culture time in 
chondrogenic medium in all constructs (Fig. 8).   There was greater alcian blue staining in 
BMSC constructs (Fig. 8A-C) compared to ASC constructs (Fig. 8D-F) at all time points.  
Scaffold alone did not stain with alcian blue (Fig. 8G).  Von Kossa staining of calcium 
deposition also increased in constructs with longer culture time (Fig. 9) and was consistently 
most intense in BMSC constructs (Fig. 9A-C).  Scaffold alone did not stain (Fig. 9G).   
2.3.6 Scanning Electron Microscopy 
Extra cellular matrix was apparent on constructs cultured in osteogenic (Fig. 10 and 11 A) 
and chondrogenic medium (Fig. 10 and 11 B) for 21 days, compared to scaffold alone (Fig. 
10 and 11 C).  There were polygonal, osteoblasts like cells on scaffold cultured in osteogenic 
medium (Fig. 10 and 11 A).  Mineral deposits were apparent surrounding spindle-shaped 
(Fig. 10F) and polygonal cells (Fig. 11F).  Cells appeared to adhere to scaffold and assume a 
flattened appearance.  The cell morphology was distinct from constructs cultured in 
chondrogenic medium which has spherical cells embedded in dense, organized ECM (Fig. 10 
and 11 B).  After 21 days culture in adipogenic medium, ellipsoid lipoblast-like cells 
containing lipid droplets were apparent in BMSC (Fig. 10D) and ASC (Fig. 11D) constructs.  
The newly formed extra cellular matrix was distinguishable by its distinct ultra structure for 
both constructs cultured for 21 days in chondrogenic medium (Fig. 10 and 11 E).  
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Figure 7 Masson’s Trichrome staining for both BMSCs and ASCs – scaffold constructs 
after 21 days culture 
BMSCs - scaffold constructs after 21 days in adipogenic (A), chondrogenic (B), 
osteogenic (C), stromal (D) medium by Masson Trichrome staining (100x).  ASCs - 
scaffold constructs after 21 days in adipogenic (E), chondrogenic (F), osteogenic (G), 
stromal (H) medium (100x, Masson’s Trichrome, scale bar – 10 µm).   
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Figure 8 Alcian blue staining for both BMSCs and ASCs – scaffold constructs over 
culture time in chondrogenic medium 
BMSCs – scaffold (A-C) and ASCs – scaffold constructs (D-F) cultured in chondrogenic 
medium for (A&D) 7 days, (B&E) 14 days and (C&F) 21 days (63x for upper right  
image, scale bar – 40 µm; 20x for major image, scale bar – 100 µm; Alican blue stain 
with nuclear fast red counterstain). 
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Figure 9 Von Kossa staining for both BMSCs and ASCs – scaffold constructs over 
culture time in osteogenic medium 
BMSCs – scaffold (A-C) and ASCs – scaffold constructs (D-F) cultured in chondrogenic 
medium for (A&D) 7 days, (B&E) 14 days and (C&F) 21 days (63x for upper right  
image, scale bar – 40 µm; 20x for major image, scale bar – 100 µm; Von Kossa’s stain 
with nuclear fast red counterstain). 
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Figure 10 Scanning electron photomicrographs of BMSCs constructs after 21 days of 
culture in induction media at low (A,B) or high (D,E,F) magnification.  COLI scaffold 
without cells at low magnification used for comparison (C).  
Scanning electron photomicrographs of BMSCs constructs after 21 days of culture in 
osteogenic (A) or chondrogenic (B) medium at low magnification.  Collagen scaffold 
without cells or culture is provided for comparison (C).  Higher magnification images of 
construct after 21 days of culture in adipogenic (D), chondrogenic (E), and osteogenic 
(F) medium.  Red arrows point to a cell with adipocyte-like morphology (D),  neo 
extracellular matrix (E), and a cell with osteoblast-like morphology (F).   
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Figure 11 Scanning electron photomicrographs of ASCs constructs after 21 days of 
culture in induction media at low (A,B) or high (D,E,F) magnification.  COLI scaffold 
without cells at low magnification used for comparison (C). 
Scanning electron photomicrographs of ASCs constructs after 21 days of culture in 
osteogenic (A) or chondrogenic (B) medium at low magnification.  COLI scaffold 
without cells or culture is provided for comparison (C).  Higher magnification images of 
construct after 21 days of culture in adipogenic (D), chondrogenic (E), and osteogenic 
(F) medium.  Red arrows point to fat droplets (D), neo extracellular matrix (E), and 
crystals (F). 
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2.3.7 RT-PCR 
The COLI mRNA levels increased with culture time in ASC and BMSC constructs cultured 
in osteogenic medium, and levels were significantly higher in BMSC compared to ASC 
constructs after 7, 14 and 21 days of culture. The ALP mRNA levels peaked significantly in 
BMSC constructs after 7 days of culture while mRNA levels were highest significantly after 
14 days of culture for ASC constructs.  The OCN mRNA levels were significantly higher in 
BMSC constructs after 21 days of culture compared to other time points.  The mRNA levels 
of COLII and SOX9 were significantly higher in BMSC constructs compared to ASC 
constructs cultured in chondrogenic medium at all time points but day 21 (Fig. 11A).  There 
were significantly higher mRNA levels of all three adipogenic specific genes in ASC versus 
BMSC constructs after 14 days of culture while LPL was higher after 7 and 21 days of 
culture and Leptin was higher after 7 days of culture.  There were no differences among time 
points within cells type for progenitor genes NANOG and SOX2.  OCT4 mRNA levels were 
significantly lower in BMSC constructs compared to ASC constructs at all time points (Fig. 
11B).  
2.4 Discussion 
Adult stromal cells have played a vital role in human tissue regeneration over the last decade.  
In equine medicine, clinical applications of adult stromal cells have historically been geared 
toward soft tissue and cartilage regeneration[33, 126].  For translational tissue engineering 
applications, characterization of three major components, cell, scaffold and bioreactor, is 
required.  This study investigated adult equine BMSC and ASC loading and behavior on 
COLI scaffolds in vitro following perfusion bioreactor loading.  Overall, perfusion bioreactor 
loading was efficient and resulted in effective cell distribution for both cell types.  COLI 
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A.  
B.  
Figure 12 Tissue-specific gene expressions of both ASCs and BMSCs after 7, 14 and 21 
days in induction media.  
A. ΔCT value change in osteogenic genes (ALP, Osteocalcin and Collagen I) and 
chondrogenic genes (Sox9 and Collagen II) of both ASCs and BMSCs on collagen 
scaffolds in osteogenic medium and chondrogenic medium repectively for 7, 14 and 21 
days. B. ΔCT value change in adipogenic genes (PPARγ, Leptin and LPL) and stemness 
genes (Oct4, Nanog and Sox2) of both ASCs and BMSCs on collagen scaffolds in 
adipogenic medium and stromal medium repectively for 7, 14 and 21 days. * indicates 
significant differences between BMSCs and ASCs at the same time points; # indicates 
significant differences over time compared with 7 days for ASCs; & indicates 
significant differences over time compared with 7 days for BMSCs. 
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scaffolds supported equine MSCs adhesion, proliferation and differentiation into three 
distinct tissue lineages.  Both BMSC and ASC constructs promoted osteogenic, chondrogenic 
and adipogenic tissue formation after induction in vitro.  This study established 
straightforward and reproducible procedures to support customized tissue engineering with 
perfusion bioreactors loading of two easy to be isolated equine MSCs onto COLI scaffold to 
grow aimed tissue type.  This achievement significantly support customized tissue 
engineering by adult MSCs for therapeutic applications in the horse.   
This study evaluated paired ASCs and BMSCs from four equine subjects and thus included 
the variations introduced by individual animals, which provided meaningful statistical 
replicates.  The relative small error bar in result section indicated low animal differences and 
proved the consistency of success specific tissue formation using the animal selection criteria, 
isolation techniques and induction conditions in this study.  This revealed great potential of 
using equine MSCs as reliable cell sources for tissue regeneration in equine clinics.  
Based on the results of this study, perfusion bioreactor loading is a reliable, consistent, and 
reproducible procedure for adult equine MSC loading.  Cell loading onto scaffolds is a 
critical step in tissue engineering, and both ASCs and BMSCs had high loading efficiency on 
collagen scaffolds at the perfusion rate used in this study.  The findings are supported by the 
studies with the adhesion of ASCs and BMSCs on channeled elastomeric scaffolds in earlier 
report [44].  In this study, the perfusion rate was determined for efficient mass transfer and 
low shear force stimulation.  Fluid flow is critical to the balance between nutrient exchange 
and shear force stimulation and affects loading efficiency.  There is an inverse correlation 
between flow rates for seeding proficiency and seeding efficiency.  Seeding efficiency 
decreases as the flow rate increase at the same seeding density [152].  Applied flow rates 
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vary for different perfusion systems [116, 153] but still remain with a range of 0.1085 ml/min 
~ 1.0850 ml/min (calculated from 0.1 mm/s ~ 1.0 mm/s) which includes that of this study.  
For other perfusion seeding, the maximum average seeding efficiency achieved was 51.9% 
[153].  Average seeding efficiency with 87% has been achieved with the same perfusion 
seeding technique under equal flow rate for 2 hours loading for both myocytes and 
endothelial cells [151], which is consistent with high seeding efficiency reached for both 
equine BMSCs and ASCs.  Therefore this perfusion seeding through the scaffolds 
accomplished a critical and success step in acquiring high cell density, which is necessary for 
subsequent tissue generation.  
Immunophenotyping was applied to confirm the multipotentiality of isolated equine MSCs   
through established MSC markers in human [154] and equine [33].  The high percentage of 
BMSCs positive for CD29 and CD44 are comparable with the previous findings of equine 
mesenchymal progenitor cells after 7 days culture, with much higher expression of CD 90 
[155].  The consistency among all these three markers indicated more accurate cell sorting 
and high percentage of multipotential cells derived by the protocol established in this study.  
Similar pattern of surface antigen expression between BMSCs and ASCs was supported by 
previous studies [156].  However, there are relatively lower percentage of MSC surface 
marker of both BMSCs and ASCs expressed in equine compared with human [154]. The 
homogeneity of cells increases with higher passage cells.  The heterogeneity of both equine 
MSCs may be due to their lower passage number used in this study compared to that of 
human cells.  Taking advantage of cell immunophenotyping characterization before loading 
can be useful and beneficial for enhanced isolation of MSCs and screening cells guaranteed 
capable to commit further multiple differentiations.  
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Cell viability on scaffolds was evaluated to assess cell distribution on scaffold.  It is an 
important parameter to estimate the effects of loading and subsequent cell growth situation 
on scaffolds.  After 2 hours of perfusion loading, cell viability maintained high on scaffold, 
indicating the flow rate and loading time were not damaging.  The limitations of tissue 
generation on scaffolds needed to be considered here is that cells reside in the center of 
scaffold died, forming necrotic center [157].  This is largely caused by the diffusional 
restrictions of oxygen penetration (less than 10 µm) [158].  However, all cell/scaffold 
constructs in center sections showed relative similar cell viability compared with surface 
sections as shown in results.  This may lead to the conclusion that with efficient loading, 
static culture could provide appropriate environment for cell growth on this highly porous 
COLI foam scaffold structure with 2 mm thickness. Further studies should be conducted to 
evaluate the cell viability with dynamic culture as well as cell viability on thicker scaffold.  It 
is expected that the high cell seeding efficiency on scaffolds can be achieved to mimic the 
physiologic cell density in engineering tissues.  
Collagen, as an important component of bone, has the advantage of biocompatibility and 
biodegradability. In previous studies, collagen/hyaluronate matrix demonstrated high 
biocompatibility and osteoconductive in treating created cranial bone defects in rats[59].  
Created bone defects in rat tibia implanted with collagen scaffolds presented a low 
inflammatory response and bone formation within a short period of time [60].  Collagen 
matrix is considered a promising choice for bone defects treatment because of its low cost of 
production associated to the biocompatibility and osteoconductivity.  It was also 
demonstrated in a recent study that collagen has the potential to induce and maintain 
chondrogenesis of equine ASCs, which promoted application of ASCs for cartilage repair in 
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equine tissue regeneration [159].  In this in vitro study, both equine BMSCs and ASCs 
demonstrated early commitment to osteogenic and chondrogenic lineages, which is 
confirmed respectively by fibro-cartilaginous and hyaline like extra cellular matrix integrated 
properly with collagen scaffold indicated by Masson’s Trichrome staining.  It is also 
mentioned that the osteoblast needs to adhere and spread on the surface of the implant in 
order to proliferate and subsequently produce ECM components, which was also shown by 
results of scanning electron microcopy [160].  Besides, collagen scaffold has also been used 
for dermal regeneration in a nude mice full skin defect model because it can serve as a 
backbone for cell infiltration and vascularization [61], which was presented in this study as 
well by the cell high affinity to collagen scaffold and contents.  These morphological results 
further confirmed multipotentiality of adult equine stromal cells and supported the ability of 
cell - scaffold construct as an efficient biocompatible implant for tissue generation. 
Overall, tissue specific micro- and ultrastructure changes supported suitability of both BMSC 
and ASC construct into adipogenic, osteogenic and chondrogenic lineages.  Temporal 
analysis of tissue specific marker genes expressions were especially useful to confirm 
differentiations and showed consist results.  Some common bone-specific genes and proteins 
are ALP, COLI and OCN [161-162].  There were significant upregulations of ALP in both 
cell types on scaffolds after 14 days induction compared with day 0, indicating higher 
percentage of osteoblasts phenotype cells.  The upregulations of COLI over time confirmed 
the osteogenic progression of both cells on scaffolds.  The level of COLI in BMSCs was 
significantly higher than that in ASCs at all time points, which showed the advantage of 
BMSCs in osteogenic differentiation on scaffold compared with ASCs.  The OCN level of 
BMSCs was significantly higher than ASCs at day 21, supporting better osteogenic 
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maturation of BMSCs on scaffolds.  Increases expression levels of COLII and SOX9 are 
normally corresponding to enhanced and stronger matrix production, which provides cues for 
chondrogenic differentiation [163].  The significant increase of COLII in both cells 
demonstrated their chondrogenic maturation over time.  The quicker progression of BMSCs 
into chondrogenesis on scaffolds compared with ASCs can be proved by the fact that both 
COLII at day 7 and 14 and SOX9 at all time points were expressed significantly higher in 
BMSCs than ASCs.  The adipogenic induced cells with upregulated genes such as PPARγ, 
Leptin and LPL were positive for lipid accumulation and were committed to adipogenesis by 
Oil Red O stain [164-165].  Significantly increase in Leptin expression of BMSCs confirmed 
its progression into adipogenic lineage.  Both leptin at day 7 and 14 and LPL at all time 
points was significantly upregulated in ASCs compared with BMSCs. This indicated ASCs 
higher tendency to commit to adipogenesis differentiation on scaffolds.  COLI scaffold 
proved able to support adipogenic, chondrogenic and osteogenic differentiation of both cells 
and provides a promising platform for specific tissue formation in vitro, demonstrated by 
their micro- and ultrastructure as well as tissue specific gene expressions. With gene level 
quantification, it was further revealed that BMSCs are more commitment to chondrogenic 
and osteogenic differentiation while ASCs are easier into adipogenic differentiation.  
This study evaluated the in vitro behavior of two types of adult equine MSCs on COLI 
scaffolds. Both cell types had high viability and DNA contents, confirming the suitability of 
collagen scaffolds for cell growth. Furthermore, collagen scaffolds supported cell 
differentiation into distinct mesenchymal tissues committed to adipogenic, chondrogenic and 
osteogenic lineages. This study, as one of the first, offers a promising platform for equine 
tissue regeneration.  More attention should be paid to the cell/scaffold construct interaction 
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with native tissue in vivo and especially to how the initial induction of cells in vitro 
influences cell behavior on scaffold and cell integration with specific tissue type in vivo.  The 
developed cell adhesion, growth and induction behavior on collagen scaffold will be further 
applied in vivo in nude mice to investigate their great potential role in equine veterinary 
tissue regeneration.  
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CHAPTER 3. IN VIVO OSTEOGENESIS OF EQUINE MULTIPOTENT STROMAL 
CELLS ON COLLAGEN SCAFFOLDS 
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3.1 Introduction 
Our previous studies revealed that collagen (COLI) scaffolds supported MSC adhesion, 
proliferation and differentiation into three distinct tissue lineages.  The established, 
straightforward and reproducible procedure supports customized tissue engineering with 
bioreactor loading of equine multipotent stromal cells (MSCs) onto COLI scaffolds to 
generate specific tissue type.  
Infection, delayed repair and inappropriate fixation devices can cause failures of equine bone 
repair.  The investigation of equine bone regeneration is considered to be a promising method 
for accelerating bone healing as well as providing an alternative besides the conventional 
approaches.  Research of equine tissue regeneration became increasingly popular over the 
last decade [118, 162, 166-169].  But few previous studies have been aimed to focus on 
investigation of bone regeneration.  Majority of MSC therapy are applied to promote tendon 
and ligament repair.  However, this application is mainly based on empirical data and there is 
still a great potential to improve healing efficiency using proper engraftment of cells into the 
lesion site. MSCs engrafted on bioscaffolds showed success to treat cartilage degeneration 
supported by solid evidence-based studies. But high demand for equine bone regeneration is 
still largely unmet.  
The previous study accomplished the first critical step to establish suitability of MSCs 
engrafted by ColI scaffold for osteogenesis in vitro. Further in vivo studies are needed to 
investigate their osteogenesis in athymic mice before its application in equine bone 
regeneration. This study was designed to test the hypothesis that osteogenesis of MSCs 
supported by COLI scaffolds in vivo can be achieved as well as its in vitro and in vivo 
osteogenesis is comparable between BMSC- and ASC constructs.  The objective of this study 
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was to compare osteogenesis at mRNA level and ECM formation on COLI scaffolds of both 
cell types, monitor bone formation process by radiograph and reconstruct and quantify tissue 
generated by each constructs at both 2D and 3D view by microcomputed tompgraphy.  
3.2 Materials and Methods 
3.2.1 Experimental Design 
Two cohorts of nude mice (N = 4 nude mice/cohort) were subcutaneously implanted with 
scaffold loaded with BMSCs or with ASCs, which had been pre-induced in osteogenic 
medium during 2 hours loading.  One control nude mice was implanted with scaffold only. 
All nude mice were harvested 9 weeks later (Fig. 13) and assessed shortly post-mortem using 
microcomputer tomography to evaluate perimeter, porosity, volume and surface area of the 
formed callus. The osteogenesis of cell scaffold constructs was confirmed with compositional 
and mRNA analysis.  This procedure was approved by the Institutional Animal Care and Use 
Committee.    
 
Figure 13 Subcutaneous implantation of cell constructs.  
The black circle depicts a pocket containing one cell construct. A total of 6 replicates 
were implanted in each nude mice.   
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3.2.2 Radiography 
Radiographs were performed at 0, 3, 6 and 9 weeks after implantation on dorsal aspect of 
nude mice. Since the ColI scaffold was radiolucent, it was impossible to tell the position of 
scaffold if there was no bone formation, which provided a reliable measurement of newly 
generated bone formation.   
3.2.3 Microcomputed Tomography 
Cell scaffold constructs were evaluated by microcomputed tomography (Micro-CT) shortly 
after postmortem according to previous published protocol [170].  Briefly, 2D micro-CT 
imaging was taken by slides with 0.04 mm thickness (SkyScan 1074, Skyscan n.v., Belgium).  
2D and 3D reconstructions were generated subsequently (Mimics v 10.1, Materialise, Ann 
Arbor, MI). Total area (µm2), bone perimeter (µm), and percent porosity (%) of generated 
tissues were measured on 2D images and total volume (mm3) and surface area (mm2) of 
generated tissues were measured on 3D images by Mimics or CTan software packages, 
respectively.  
3.2.4 Compositional Analysis 
All compositional analysis was performed according to published manufacture’s protocols. 
3.2.4.1 DNA Content 
Cell quantity on scaffolds was evaluated by DNA content using the quantative picogreen 
assay kit (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. Briefly, 50 µl of a 
papain digested sample was mixed with 50 µl picogreen reagent in a clear 96 well plate and 
incubated at room temperature for 5 min in the dark. The plate was read immediately using 
fluorescence microplate reader (Synergy HT, Winooski, VT) at the wavelength for 
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fluorescein (excitation 485 nm and emission 538 nm). Amount of DNA content was 
calculated based on the standard curve.  
3.2.4.2 Protein Assay 
Modified lowry method was used to measure the quantity of total proteins [171].  150 µl of 
biuret reagent (Sigma, St Louis, MO) was added to 50 µl of sample and standard (bovine 
serum albumin) in a clear 96 well plate and incubated for 15 min at room temperature. 15 µl 
of 1N Folin and Ciocalteau’s reagent (Sigma, St Louis, MO) was added to each well and 
mixed. Absorbance at 650nm was measured after 30 min incubation at room temperature. 
Samples were diluted to fit into the standard curve range if needed. 
3.2.4.3 BMMB Assay 
Quantification of sulfated glycosaminoglycan (sGAG) was performed according to a 
published protocol[172]. DMMB solution was prepared by dissolving 21 mg of 1,9-  
dimethylmethylene blue (Sigma, St Louis, MO) in 5ml ethanol and 2.0 g of sodium formate 
in water separately.  pH of the combined solution was adjusted with concentrated formic acid 
to 3.0 in a final volume of 1 liter. In a clear 96 well plate, 200µl DMMB solution was added 
to 40 µl of sample and standard. Absorbance was measured at 520 nm immediately after 
mixing using a microplate reader (Synergy HT, Winooski, VT). Chondroitin sulfate (Sigma, 
St Louis, MO) was used as standard and concentration of GAG in samples was determined 
from the standard curve. 
3.2.4.4 DMBA Assay 
Determination of hydroxy proline (total collagen) was measured according to the published 
protocol [173]. Briefly, 50 µl of concentrated HCl was added to 50 µl of papain digestion 
 59 
 
buffer and incubated for 18 hrs at 110°C.  Samples were dried by heating to about 50°C in a 
fume hood after hydrolysis and resuspended in acetate citrate buffer.  50 µl of 1.27% 
chloramines (Sigma, St Louis, MO) prepared in water was added to 50 µl of hydrolyzed 
sample and incubated at room temperature for 25 min. 15% of p-
dimethylaminobenzaldehyde (DMBA) (Sigma, St Louis, MO) was dissolved in n- 
propanol/perchloric acid (2:1) after addition of 50 µl of Ehrlich’s reagent.  The mixture of 
DMBA and samples were incubated at 60 °C for 20 min and cooled to room temperature. 
The plate was read at 550 nm. The standard curve was generated with hydroxyproline (Sigma, 
St Louis, MO). 
3.2.5 RT-PCR 
Constructs were stored in TRI Reagent at -80°C following culture.  Constructs were 
homogenized in tissue lyzer (Qiagen, Valencia, CA) and then RNA was isolated according to 
the manufacturer’s protocol.  After DNase treatment, RNA was reversely transcribed to 
cDNA using oligo dT and M-MLV reverse transcriptase (Sigma, St Louis, MO).  Real time 
polymerase chain reaction was performed using SYBR Green supermix (Bio-Rad, Hercules, 
CA) with ABI Prism 7900HT sequence detection system (Applied Biosystem, Foster City, 
CA).  Equine-specific primers for osteogenic (osteocalcin [OCN], alkaline phosphatase 
[ALP], canabinoid1 [CB1] and bone sialo protein [BSP]) were used for analyses (Table 3).  
The housekeeping gene, Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH), was 
used to determine the ΔCt value for each gene of interest.   
3.3 Results 
The size of COLI scaffolds in control group decreased dramatically, which indicated the 
degradation of scaffold.  Both ASC- and BMSC constructs remained the same position with  
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Table 3 Primer sequence of bone specific genes 
Genes Forward Primers Reverse Primers 
ALP ACACTCAAGGGAGAGGTCCA CTGCCCAAGAGAGAAACCTG 
OCN GCGCTCTGTCTCTCTGACCT GCCGGAGTCTGTTCACTACC 
CB1 AGGAGCAAGGACCTGAGACA CATGCTGGCTGTGTTATTGG 
BSP CAGCCATGAGTCAAGTCAGC CTTGTGGCTCTGATGTTCCA 
 
A. B. C.  
Figure 14 Pictures showing the representative anatomical view of constructs 
progression after 9 weeks postmortem. A). COLI scaffolds only as control, B). ASC 
constructs, C). BMSC constructs. 
A). Very small portion of COLI scaffolds in control group remained at the implantation 
sites.  B). ASC constructs progressed into a uniformly structured tissue integrated with 
the skin tissue of nude mice.  C). BMSC constructs progressed into denser tissue 
embedded within the constructs.   
 
similar size as original scaffold implanted.  However, by close examination, it was revealed 
that ASC constructs progressed into a uniformly structured tissue integrated with in close 
proximity to vascularization under the skin while BMSC constructs generated yellowish hard 
pieces of bone-like tissue embedded within the constructs (Fig. 14).   
This finding at harvest was further confirmed by radiograph taken 9 weeks after implantation. 
Because COLI scaffolds were radiolucent, the degraded COLI scaffolds were invisible on 
radiograph (Fig. 15A).  Based on the fact that the newly generated tissue by ASC constructs 
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were also invisible on radiograph, it was confirmative that ASC constructs did not generate 
bone tissue but more like part of dermal tissue (Fig. 15B).  After comparison, BMSC 
constructs generated bone tissue according to this radiograph (Fig. 15C). The newly 
generated bone was present as early as 3 weeks post-implantation (Fig. 16B).  The size of 
newly generated bone did not increase dramatically over time, which indicated the bone 
formation was guided and controlled by original scaffold size (Fig. 16C&D).  
A. B. C.  
Figure 15 Radiograph evaluation of bone formation 9 weeks after implantation (A. 
COLI scaffolds only as control, B. ASC-COLI constructs, C. BMSC-COLI constructs). 
A). COLI scaffolds only were radiolucent. B). Tissue generated by ASC constructs were 
also radiolucent. C) BMSC construct generated bone tissue captured by radiograph 
indicated by red circle 
There were significantly higher 2-D surface area and 3-D total volume and lower porosity for 
ASC constructs, indicating more uniform distributed ECM formation (Fig. 17).  Tissue 
generated on both constructs showed similar shape directed by ColI scaffold, indicated by 
their comparable 2-D perimeter and 3-D surface area (Fig. 17). These findings were further 
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demonstrated by reconstructed 3D structure of newly formed tissue with higher porosity of 
BMSCs constructs and more uniform structure of ASC constructs (Fig. 18). In summary, the 
fact that the newly generated tissue was guided by original shape of scaffold suggested that 
the COLI scaffold, serving as a temporary structure support, its degradation rate is balanced 
with new tissue formation rate. 
There were no significant differences between ASCs and BMSCs for HPR, GAG and protein 
expressed on scaffolds normalized to DNA contents, which indicated indistinguishable 
ability between ASCs and BMSCs to synthesize ECM in the form of collagen and GAG (Fig. 
19).   
There were significant upregulations of ALP, OCN and BSP, indicating enhanced 
osteogenesis of BMSC constructs.  Because BSP is an important component of bone ECM, 
significant increased expression of BSP suggested that ECM formed by BMSC constructs is 
likely to contribute to bone formation.  After 9 weeks of implantation, bone formation in 
BMSC constructs suggested activities of mature osteoblast.  No differences of CB1 
expression between ASC- and BMSC constructs might suggest CB1 receptor did not play a 
role in mature osteoblasts (Fig. 20).  
3.4 Discussion 
Adult equine MSCs for multiple tissue regeneration have gained great attention as the 
treatment choice for equine orthopedic lesions over the last decade [14].  Current equine 
regenerative medicine is largely geared to MSCs administration as a single product or in 
combination with the heterogeneous non-expanded progenitor cell population. Besides, 
clinical applications of adult stromal cells therapy have been mainly focused on soft tissue 
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A.  
Figure 16 Radiograph evaluation of bone formation by BMSC-COLI constructs (A. 0 
week, B. 3 weeks, C. 6 weeks and D. 9 weeks post-implantation).  
A). BMSC constructs were radiolucent immediately after implantation. B). Bone tissue 
generated by one of BMSC constructs was captured by radiograph as early as week 3. 
C). Two of BMSC constructs generated bone tissue and the size of bone tissue generated 
at week 3 increased after 6 weeks of implantation. D). Generated bone tissue remained 
similar size and shape after 9 weeks of implantation.  
B. C.  D.  
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Figure 17 Micro-CT measurements of tissue formation in 2D and 3D view for both 
ASCs and BMSCs.   
Significant higher 2-D surface area and 3-D total volume and significant lower porosity 
for ASC constructs indicated more uniform distributed ECM formation on ASC 
constructs.  Tissue generated on both constructs showed similar shape indicated by 
their indistinguishable 2-D perimeter and 3-D surface area. 
 
 65 
 
A. B.  
Figure 18 Representative reconstructed 3D images of generated tissue by BMSC 
constructs (A) by selecting bone density and ASC constructs (B) by selecting soft tissue 
density.   
Bone tissue produced by BMSCs constructs (A) showed higher porosity than soft tissue 
generated by ASCs constructs (B).  ASC constructs demonstrated more uniform 
structure.  
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Figure 19 ECM formation on BMSC- and ASC constructs  
Quantification of HPR, GAG and protein on BMSC- and ASC constructs which has 
been normalized by DNA content. 
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Figure 20 Bone specific gene expressions by BMSCs and ASCs on COLI scaffolds 
implanted in vivo.  
ΔCT value change in osteogenic genes (ALP, OCN, BSP and CB1) of both ASCs and 
BMSCs on COLI scaffolds after 9 weeks of implantation. * indicates significant 
differences between BMSCs and ASCs.  
and cartilage regeneration.  Although recent development of MSCs engrafted on bioscaffolds 
showed success for tissue regeneration, they were mainly aimed to treat cartilage 
degeneration.  There are still largely unmet needs for equine bone regeneration that can be 
addressed by studies of optimization of MSC-bioscaffold interaction and pre-induction 
condition to achieve bone regeneration in clinics in the near future. This study investigated 
adult equine BMSC and ASC osteogenesis on COLI scaffolds in vivo based on established 
procedures in a previous study.  Overall, COLI scaffolds supported equine MSCs adhesion, 
ECM production and differentiation with BMSC constructs more committed towards 
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osteogenesis and ASC constructs more committed towards dermal-like tissue. This 
achievement significantly supported engineered tissue by adult MSCs for therapeutic 
applications in the horse especially for bone regeneration.   
Based on results from radiograph, there was radiopague bone tissue formation of BMSC 
construct as early as 3 weeks post-implantation, which proved BMSC-COLI constructs as a 
promising and efficient therapy for equine bone repair especially for acute injuries.  Although 
ASC constructs did not show any bone formation based on radiograph, they produced similar 
ECM as BMSC to form dermal-like tissue. Based on micro-CT, both ASC- and BMSC 
construct generated tissue had similar size, indicating that the degradation of COLI scaffold 
was balanced with newly formed tissue. COLI scaffolds served successfully as a temporary 
structure for new tissue to form.  
It was proved by this study that short-term induction in vitro is sufficient to trigger 
osteogenesis of BMSC subcutaneously in vivo, which significantly improves efficiency of 
bone repair in equine clinics in near future. However, lack of consistent distribution and 
uniform shape for bone formed by BMSC constructs may be due to insufficient vascular 
supplies subcutaneously.  ASC constructs produced comparative ECM as that of BMSC 
constructs but under commitment into dermal-like tissue, indicating ASCs more responsive 
to signal cues encountered subcutaneously due to their original niches.  This finding was 
consistent with significant upregulation of osteogenic genes in BMSC constructs, confirming 
bone regeneration by BMSC construct.  
Further study should be conducted to optimize the pre-induction time as well as to introduce 
osteoinductive component to COLI scaffold to improve efficiency of ASCs constructs to 
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commit osteogensis differentiation. Considering the key advantage of ASCs with high 
harvest rate, easy isolation from autologous fat tissue, minimal injury to donor site and still 
with equal multipotentiality as BMSCs, it is necessary to investigate and establish the role of 
ASCs in equine bone regeneration to provide more alternative for clinicians as well as 
improve the efficiency of bone repair in equine clinics.  
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CHAPTER 4. OPTIMIZED LOADING AND PRE-CULTURE CONDITIONS FOR 
ADULT HUMAN ADIPOSE-DERIVED MULTIPOTENT STROMAL CELL 
OSTEOGENESIS ON BIOCOMPATIBLE SCAFFOLDS 
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4.1 Introduction 
There are more than 500,000 bone graft procedures in the United States and approximately 
2.2 million are performed worldwide each year [174].  The associated annual cost of these 
procedures is estimated to 2.5 billion US dollars.  Either autografts or allografts are the 
primary choice of grafts and are used in 90% of procedures.  Harvesting the autografts 
requires an additional surgery at the donor site and quantities of bone tissue available for 
harvest are also limited.  Due to these limitations of autologous bone graft, various 
commercially available synthetic bone graft substitutes have been developed.  However, 
bone graft substitutes usually do not have the same osteogenic capacity as autologous bone 
[175].  Functional tissue can be regenerated using differentiated cells or multipotent stromal 
cells (MSCs) engrafted on biocompatible scaffolds.  Huge selections of commercially 
available scaffolds have been developed to promote bone formation but information about 
their interactions with MSCs is limited.  There are distinct differences among scaffolds such 
as components, porosity, surface area and osteoinductive properties [176]. Since all these 
properties of the scaffolds play an important role in osteogenic tissue formation, it is critical 
to optimize scaffold and cell interactions to promote the development of functional bone 
tissue [177-178].  
Research on bone regeneration by MSCs has largely focused on bone marrow derived MSCs 
(BMSCs) because of their superiority in osteogensis.  Similar to bone marrow, adipose tissue 
also derived from the embryonic mesendoderm.  It has been reported that adipose derived 
MSCs (ASCs) have high proliferative capability and multipotentiality, including osteogenic, 
chondrogenic, and adipogenic differentiation [179-181].  Recent findings proved ASCs as a 
promising cell source in terms of their osteogenic potential [117, 169, 182-183].  
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Accessibility of ASCs in abundance from autologous fat tissue with minimal injury to the 
donor site is a key advantage over BMSCs.  The objective of this study was to evaluate ASCs 
viability, ECM formation, osteo-specific mRNA expression and ultrastructure on three 
biocompatible scaffolds, which was aimed to test hypothesis that ASCs on collagen I (COLI) 
scaffold is more superior in osteogenesis by combining osteoinductive components than 
COLI only scaffold. 
Pre-implantation culture conditions are also crucial in ASCs osteogenesis.  Studies have 
shown that cell-scaffold constructs developed bone more efficiently in vivo when constructs 
were first cultured in vitro with osteogenic medium [184-185]. However, long pre-
implantation culture is time-consuming and not desirable from aspects of clinical 
applications.  It has been shown that pre-culture of MSCs may on the other hand limit their 
proliferation potential and bone formation efficiency in vivo [186].  Therefore we 
hypothesize that short-term exposure to induction for ASCs have comparable effects on 
osteogenesis as long-term exposure after loaded on biocompatible scaffolds.  The objective 
was to determine whether the short-term pre-induction is sufficient for osteogenesis of 
chosen cell-scaffold constructs based on ECM formation and mRNA expression level. 
Scaffolds of different compositions and structures should have unique osteoinductive 
mechanisms and the knowledge of changes at molecular level will help determining the 
suitable scaffolds.  Therefore we were interested in exploring the molecular mechanism of 
osteogenesis of cell-scaffold constructs.  Bone tissue is subject to constant remodeling by 
osteoblasts and osteoclasts to balance between bone-forming and bone-resorbing activities, 
respectively.  It has been characterized that osteoprotegerin (OPG) binds to receptor activator 
of nuclear factor kappa beta ligand (RANKL), a protein expressed on osteoblast membrane, 
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to limit the access of RANKL to RANK on osteoclast and thus inhibit activation and 
differentiation of osteoclasts [187].  Therefore OPG/RANKL system plays a major role in 
bone formation and absorption.  High OPG/RANKL ratio indicates bone formation activities 
while low value is associated with bone resorption activities [188].  We investigated 
OPG/RANKL mRNA expression on ASC-scaffold constructs to confirm the involvement of 
this pathway in osteogenesis. It was further used as an indicator of osteogenesis progress to 
uncover the mechanism of other regulatory events that may be responsible for MSC 
osteogenesis.  
Recent findings demonstrated the role of the cannabinoid system in bone formation and 
regulation of bone mass [189-191].  The endocannabinod system constitutes of two 
cannabinoid receptors (CB1 & CB2).  Cannabinoid receptors belong to the G protein couple 
receptor family and mediators of cannabinoid action. Endocannabinoids are well known for 
their roles in the nervous system and the presence of cannabinoid receptors in bone and 
peripheral tissue have been reported as well [189-193]. Expression of CB1 and CB2 
osteoblast progenitors are normally very low [189] and CB2 mRNA expression increases 
when the cells are grown in osteogenic medium [194].  Studies reported that MSCs from CB1 
deficiency mice had reduced osteogenic capacity [192].  It has been shown that CB1 level of 
mature bone tissue is as low as non bone-forming tissue [192]. The significantly increased 
level of CB1 after osteogenic induction of osteoprogenitors may indicate their participation 
in early stage of osteogenesis [195].  In order to investigate the role of cannabinoid system in 
osteogenesis and further confirm their participations in ASCs osteogenesis, we investigated 
the mRNA expression level of CB1& CB2 in ASC constructs and correlation between 
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CB1&CB2 and OPG, RANKL&OPG/RANKL to explore the mechanism of cannabinoid 
pathway in adult MSC osteogenesis.  
In summary, human ASCs adhesion, viability, proliferation, ECM formation, ultrastructure 
and mRNA expression level on three commercially available scaffolds with common 
component of COLI have been investigated in both short-term and long-term osteogenic 
induction media with stromal media as control for 7, 14, 18 days to test the following 
hypotheses: 1) COLI scaffold is more superior in osteogenesis by combining osteoinductive 
components than COLI only scaffold for ASCs; 2) long- and short-term exposure to 
induction have comparable effects on osteogenesis of chosen constructs; 3) cannabinoid 
pathways are involved in ASCs osteogenesis. 
4.2 Materials and Methods 
4.2.1 Isolation of ASCs and Culture 
All procedures were approved by the University Institutional Review Board. Subcutaneous 
adipose tissue was obtained from healthy donors after informed consent.  ASCs were isolated 
from liposuction aspirates of three healthy adults [196].  Briefly, the tissue was finely minced 
and incubated in 0.01% collagenase type I (Worthington Biochemical, Lakewood, NJ) 
containing 0.1% bovine serum albumin (Sigma, St Louis, MO) in DMEM/F12 (Hyclone, 
Logan, UT) for 1 hour at 37 ºC with continuously shaking and brief agitation every 15 
minutes. At the end of the incubation, the suspension was centrifuged at 1200 rpm for 10min.  
The resulting pellet containing ASCs was suspended in stromal media composed of 
DMEM/F12, 10% characterized fetal bovine serum (Hyclone, Logan, UT), and antibiotics 
(MP biochemical, Solon, OH).  Primary isolated cells were incubated at 37 ºC in 5% CO2 
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until reaching 70% confluence.  Cells were then replated at a density of 5,000/cm2 and 
expanded up to passage 2 (70-80% confluence prior to passage) in stromal medium.  The 
culture medium was changed every 2-3 days until the end of the experiment. Cells were 
never allowed to reach 100% confluence. 
4.2.2 Cells Loading on Scaffolds 
Cells were trypsinized and loaded onto three types of scaffolds with size of 27 mm3: 1) 
Ultrafoam scaffold with bovine corium collagen type I (UF) (Avitene, Providence, RI); 2) 
Mastergraft scaffold with type I collagen and biphasic calcium phosphate ceramic composed 
of 15% hydroxyapatite and 85% β-tricalcium phosphate (MG) (Medtronic, Minneapolis, 
MN); and 3) Vitoss scaffold with 20% type I bovine collagen and 80% β-tricalcium 
phosphate (VI) (Orthovia, Malvern, PA) within a spinner flask bioreactor at a cell density of 
55,000 cells/mm3 for 2 hrs at 60-80 rpm.  Four scaffolds of the different composition were 
seeded in a spinner flask each time to ensure identical loading of different scaffold for the 
purpose of comparisons.  After 48 hours of culture in stromal medium, scaffold replicates of 
each composition were assigned to one of three culture medium: 1) stromal medium, 2) 48 
hours in osteogenic medium composed of stromal medium, 10mM beta-glycerophosphate 
(Affymatrix, Santa Clara, CA), 20nM dexamethasone (Sigma, St Louis, MO) and 0.05mM 
ascorbic acid (Sigma A, St Louis, MO) followed by stromal medium (osteo-stromal medium), 
or 3) osteogenic medium. Scaffolds were harvested for evaluation immediately after pre-
culture period (0 day), and after 7, 14 or 28 days in culture. 
4.2.3 Cell Viability  
Cell viability and distribution in the scaffolds were determined using confocal laser 
microscopy following live/dead staining (Invitrogen, Carlsbad, CA).  Scaffolds were washed 
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in PBS before incubation in staining solution containing calcein AM and 
ehtidiumhomodimer-1 (EthD-1) for 30 min in darkness. Live cells were stained green by 
calceinAM and dead cells were stained red by EthD-1. Inside the cells, calcein-AM is 
hydrolyzed by endogenous esterase into the highly negatively charged green fluorescent 
calcein, which is retained inside the cytoplasm. Scaffolds were viewed at 10x using a 
confocal laser microscope equipped with argon and rhodamine filters (Leica TCS SP2, 
Buffalo Grove, IL).  A total of 50 sequential digital photomicrographs were generated from 
one surface to the other in the Z plane of each scaffold.  Digital images were exported as 
JEPG images and total cell number was evaluated using graphics software (Image-Pro, 
Media Cybernetics, Bethesda, MD).  The area of each section is 1.44 mm2 and cells in 50 
sections were counted. So a total cell area of 72 mm2 was counted. 
4.2.4 RT-PCR 
Quantitative PCR was performed to determine the relative expression of the osteogenic genes 
as well as regulatory genes of the osteogenesis pathway. Tissue samples were placed in RNA 
later solution (Qiagen, Valencia, CA), stored at 4oC overnight, and then stored at -20 0C until 
needed.  Total RNA was isolated from the samples using tri reagent (Sigma, St Louis, MO) 
after lysis in a tissue lyser (Qiagen, Valencia, CA).  Concentration and quality of isolated 
RNA was determined using spectrophotometer (Nanodrop, Wilmington, DE).  After DNAase 
treatment, 2µg RNA was reversly transcribed to cDNA using oligo dT and M-MLV reverse 
transcriptase (Sigma, St Louis, MO). Real time polymerase chain reaction was performed 
using SYBR green supermix (Bio-Rad) with ABI Prism 7900HT sequence detection system 
(Applied Biosystem, Foster City, CA) to analyze relative gene expression. Primers (Sigma, 
St Louis, MO) were designed using Primer 3 software (MIT).  Primer sequences are shown 
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in the Table 4.  PCR for all genes was run at the same standard cyclic condition, with an 
initial activation of taq polymerase at 95 for 3 min, followed by 45 cycles of 95 °C/ 15 sec 
and 60 °C/ 1 min. A dissociation step (95 °C/ 15; 60 °C/ 15 sec; 95 °C/ 15 sec) was added at 
the end to check PCR product by a dissociation curve. Each sample was run in duplicate with 
non-template samples of both water and reverse transcriptase negative RNA. Levels of 
mRNA corresponding genes were quantified using the 2-ΔΔCt method. Ct values of target 
genes were normalized by the Ct of housekeeping gene, GAPDH, to obtain the ΔCt values. 
Table 4 Primer sequence for genes quantified in this study 
Markers Genes Forward Primers Reverse Primers 
Osteogenic ALP GCTGAACAGGAACAACGTGA CCTTCCACCAGCAAGAAGAA 
 Osteocalcin GACTGTGACGAGTTGGCTGA AAAGAAGGGTGCCTGGAGAG 
Regulatory OPG AACCCCAGAGCGAAATAC AAGAATGCCTCCTCACAC 
 RANKL ACG GTCTGGAGAGGAAATCA TCCAAAAACTGGGGCTCA 
Receptor CB1 CGATACACTTGGCATTGACG AACCACGAGCAAAGGAGAGA 
 CB2 CAATGAGGGACTTGGGAGAA GGCCTTGACAATTAGGCAGA 
Housekeeping GAPDH ATGTTCGTCATGGGTGTGAA GTCTTCTGGGTGGCAGTGAT 
4.2.5 Sample Preparation for Compositional Analysis 
Lyophilized samples were digested with immobilized papain in digestion buffer (2 mg papain, 
100mM sodium acetate and 10 mM EDTA) overnight at 60 °C on a shaker (Labnet, 
Woodbridge, NJ) at 60 rpm.  Scaffolds without cells were used as controls. Supernatants 
were collected after centrifugation for 10min at 4000 rpm and stored at -80 °C until ready to 
be analyzed.  
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4.2.6 DNA Content 
ASCs growth on scaffolds was evaluated by DNA content using the quantative picogreen 
assay kit (Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. Briefly, 50 µl of a 
papain digested sample was mixed with 50 µl picogreen reagent in a clear 96 well plate and 
incubated at room temperature for 5 min in the dark. The plate was read immediately using 
fluorescence microplate reader (Synergy HT, Winooski, VT) at the wavelength for 
fluorescein (excitation 485 nm and emission 538 nm). Amount of DNA content was 
calculated based on the standard curve.  
4.2.7 Protein Assay 
Modified lowry method was used to measure the quantity of total proteins [171].  150 µl of 
biuret reagent (Sigma, St Louis, MO) was added to 50 µl of sample and standard (bovine 
serum albumin) in a clear 96 well plate and incubated for 15 min at room temperature. 15 µl 
of 1N Folin and Ciocalteau’s reagent (Sigma, St Louis, MO) was added to each well and 
mixed. Absorbance at 650nm was measured after 30 min incubation at room temperature. 
Samples were diluted to fit into the standard curve range if needed. 
4.2.8 BMMB Assay 
Quantification of sulfated glycosaminoglycan (sGAG) was performed according to a 
published protocol[172]. DMMB solution was prepared by dissolving 21 mg of 1,9-  
dimethylmethylene blue (Sigma, St Louis, MO) in 5ml ethanol and 2.0 g of sodium formate 
in water separately.  pH of the combined solution was adjusted with concentrated formic acid 
to 3.0 in a final volume of 1 liter. In a clear 96 well plate, 200µl DMMB solution was added 
to 40 µl of sample and standard. Absorbance was measured at 520 nm immediately after 
mixing using a microplate reader (Synergy HT, Winooski, VT). Chondroitin sulfate (Sigma, 
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St Louis, MO) was used as standard and concentration of GAG in samples was determined 
from the standard curve. 
4.2.9 DMBA Assay 
Determination of hydroxy proline (total collagen) was measured according to the published 
protocol [173]. Briefly, 50 µl of concentrated HCl was added to 50 µl of papain digestion 
buffer and incubated for 18 hrs at 110°C.  Samples were dried by heating to about 50°C in a 
fume hood after hydrolysis and resuspended in acetate citrate buffer.  50 µl of 1.27% 
chloramines (Sigma, St Louis, MO) prepared in water was added to 50 µl of hydrolyzed 
sample and incubated at room temperature for 25 min. 15% of p-
dimethylaminobenzaldehyde (DMBA) (Sigma, St Louis, MO) was dissolved in n- 
propanol/perchloric acid (2:1) after addition of 50 µl of Ehrlich’s reagent.  The mixture of 
DMBA and samples were incubated at 60 °C for 20 min and cooled to room temperature. 
The plate was read at 550 nm. The standard curve was generated with hydroxyproline (Sigma, 
St Louis, MO). 
4.2.10 Scanning Electron Microscopy 
Surface morphology, ECM formation of scaffolds and cell distribution on scaffolds were 
evaluated using a scanning electron microscope (SEM) (Quanta 200, FEI Company, 
Hillsboro, OR). The cell constructs were rinsed with PBS and fixed with 2.5% 
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for an hour, post fixed for 48 h in 
0.1% osmium tetroxide (OsO4), and then dehydrated through the ethanol series (50% to 
100%). After critical point dry, the samples were then sputter coated with gold and imaged 
with SEM at 15 kVP.      
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4.2.11 Statistical Analysis 
All results were expressed as mean ± standard deviation (SD).  Data was analyzed with one-
way analysis of variance (ANOVA), followed by Tukey’s post hoc test.  For all comparisons, 
significance was set at p<0.05. 
4.3 Results 
4.3.1 Osteogenic Potential of ASCs 
The osteogenesis of ASCs potential was verified by alizarin red staining of calcium 
deposition after 21 days of osteogenic induction (Fig. 21A). Calcium staining was negative 
for hASCs cultured for 21 days in stromal cultures (Fig. 21B). 
A. B.  
Figure 21 Alizarin red stain to show osteogenic potential of ASCs after 21 days 
induction in osteogenic medium (A) and stromal medium (B). 
Calcium deposition was positive indicated by Alizarin red stain to show osteogenesis of 
ASCs after 21 days induction in osteogenic medium (A) and no calcium deposition 
confirmed no osteogenesis of ASCs in stromal medium (B). 
 81 
 
4.3.2 Cell Distribution and Viability 
Cell viability was greater than 70% at all time points, indicating that cell scaffold constructs 
remained relatively viable at all time points.  Number of viable cells was highest in the UF 
scaffold with lower viable cell numbers but comparable cell number in MG and VI scaffolds 
(Fig. 22).  
 
Figure 22 Mean±SD of cell counts on all three scaffolds with different culture time and 
culture medium.  
Mean±SD of cell counts on all three scaffolds (top-UI, middle-MG, bottom-VI) in 
stromal, osteo-stromal, osteogenic medium for 0, 7, 14 and 28 days.  
4.3.3 Expression of Osteogenic Marker 
mRNA levels of osteogenic markers ALP and OCN were upregulated at all time points in all 
scaffolds.  There is a significant increase in mRNA levels of ALP after 14 days of induction 
for UF and 7 days for MG but no significant increase observed in VI (Fig. 23A). Short-term 
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exposure to osteogenic media showed early (7 day) induction only for MG but this is a 
transient induction which disappears gradually after withdrawal of induction media. There 
were significant differences in expression of ALP between UF and MG and also between VI 
and MG but not between UF and VI. After 14 days in induction medium, the mean fold 
change in ALP mRNA for UF, MG and VI was 18.13, 18.37 and 5.0 respectively. OCN were 
late responsive markers and showed increased expression after 28 days of induction (Fig. 
23B) but only MG showed significant upregulation. MG induced the greatest expression of 
these osteogenic markers and VI had the least upregulation.  
A. B.  
Figure 23 Mean±SD fold changes of both ALP (A) and OCN (B) expression of hASCs 
on all three different scaffolds in all three media for all time points. 
Mean±SD fold changes of both ALP (A) and OCN (B) expression of hASCs on all three 
different scaffolds (top-UI, middle-MG, bottom-VI) in stromal, osteo-stromal, 
osteogenic medium for 7, 14 and 28 days respectively.  Significant differences are 
indicated by *, ** and *** within the same time points among different medium and by 
a, b and c within the same medium type among different time points.   
 83 
 
4.3.4 Expression of Regulatory Genes 
mRNA levels of RANKL were significantly decreased and OPG mRNA expression was up 
regulated on all scaffolds cultured in osteogenic medium, resulting in increases in the 
OPG/RANKL ratio. After 28 days in osteogenic medium, the mean OPG/RANKL ratio in 
UF scaffold was 67.8, MG 90.4 and VI 6.22 fold higher than that in pre-culture scaffolds (Fig. 
24). 
 
Figure 24 Mean±SD fold changes of OPG/RANKL expression of ASCs on all three 
different scaffolds in all three media for all time points.  
Mean±SD fold changes of OPG/RANKL expression of ASCs on all three different 
scaffolds (top-UI, middle-MG, bottom-VI) in stromal, osteo-stromal, osteogenic medium 
for 7, 14 and 21 days respectively.  Significant differences are indicated by *, ** and *** 
within the same time points among different medium and by a, b and c within the same 
medium type among different time points.     
4.3.5 Expression of Cannabinoid Receptor Genes 
There was a significant induction in the mRNA expression of CB1 in the induction group for 
all scaffolds, however, the UF showed the greatest induction. After 14 days in osteogenic 
medium, the fold changes in the UF scaffold was 46,000, MG 22,955 and VI 5,647 fold 
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higher relative to pre-culture scaffolds (Fig. 25A). On the other hand, CB2 showed a 
moderate and mixed trend in mRNA expression. Spontaneous induction was observed in all 
scaffolds. When cultured in osteoinductive media, there was induction in MG but reduction 
both for UF and VI scaffold (Fig. 25B).  
A. B.  
Figure 25 Mean±SD fold changes of CB1 (A) and CB2 (B) expression of ASCs on all 
three different scaffolds in all three media for all time points.  
Mean±SD fold changes of CB1(A) and CB2 (B) expression of ASCs on all three 
different scaffolds (top-UI, middle-MG, bottom-VI) in stromal, osteo-stromal, 
osteogenic medium for 7, 14 and 21 days respectively.  Significant differences are 
indicated by *, ** and *** within the same time points among different medium and by 
a, b and c within the same medium type among different time points.   
4.3.6 Correlations Between Regulatory Genes and Cannabinoid Receptor Genes 
There were significant positive correlations between OPG/RANKL ratio and CB1 expressed 
on all three scaffolds.  The positive correlation between OPG/RANKL and CB2 was 
significant only on MG scaffolds.  Additionally, the correlations between RANKL and both 
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CB1 and CB2 were negative and significant on MG scaffolds. For OPG expression, it only 
had significant correlation with CB2 expressed on VI scaffolds (Table 5). 
Table 5 Pearson correlations between OPG, RANKL, OPG/RANKL and CB1, CB2 
expressed on all three different scaffolds.  
 Variable CB1 CB2 
UF OPG 0.18384 (p=0.6359) -0.04509 (p=0.9083) 
 RANKL -0.50054 (p=0.1699) 0.50682 (p=0.1638) 
 OPG/RANKL 0.74105 (p=0.0223) -0.39111 (p=0.2979) 
MG OPG -0.00221(p=0.9955) -0.04264 (p=0.9133) 
 RANKL -0.68308 (p=0.0425) -0.71406 (p=0.0307) 
 OPG/RANKL 0.69098 (p=0.0393) 0.86349 (p=0.0027) 
VI OPG -0.3847 (p=0.3029) 0.82629 (p=0.0060) 
 RANKL 0.54828 (p=0.1264) 0.37384 (p=0.3216) 
 OPG/RANKL 0.83097 (p=0.0055) -0.02481 (p=0.9495) 
4.3.7 Biochemical Analysis 
There were increases in DNA content on all scaffolds with maximum DNA levels after 7 
days in culture and the greatest increase on the MG scaffold (Fig. 26A). Total GAG was 
significantly increased on the UF scaffold after 28 days, while on the MG scaffold there was 
a significant increase after 7 days of culture and remained elevated until the end of the study 
(Fig. 26B). There were no significant changes of collagen contents on the VI. Only the UF 
scaffold showed significant induction of collagen after 14 days in induction media (Fig. 26C). 
No significant changes in protein content were observed (Fig. 26D). 
4.3.8 Cell Adhesion and Morphology 
Cell morphology and formation of ECM on the surface of cell-scaffold constructs was 
evaluated by SEM images.  By comparing among three different scaffolds, UF had the most 
porous structure while VI had very few pores, indicating that porous structure was largely 
determined by ColI components (Fig. 27A, C and E).  ASC adhered on the surface formed 
sheets covering the pores of scaffolds after 7 days of culture. There was apparent ECM 
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formation on all constructs under induction with most enhanced formation on UF. Cells and 
ECM appeared to cover pores of UF scaffold and assumed a uniform appearance (Fig. 27B). 
ECM mineralization was most apparent on VI scaffolds (Fig. 27F).  
4.4 Discussion  
Ideal biomaterials for osteogenesis should support cell attachment, migration, proliferation, 
and stimulate new bone formation. A wide selection of commercial scaffolds is available for 
clinical practice but physiochemical properties of these scaffolds are different.  The 
multipotentiality of ASCs has been well established [16-18]. Adipose tissue is available in 
large quantities and is easily accessible, making ASCs a promising cell source for 
regenerative medicine. Therefore in the present study, we used an in vitro culture of ASCs to 
A. B. C. D.  
Figure 26 Mean±SD fold changes of DNA (A), GAG (B), collagen (C) and total protein 
(D) quantified on all three different scaffolds. 
Mean±SD fold changes of DNA (A), GAG (B), collagen (C) and total protein (D) 
quantified on all three different scaffolds (top-UI, middle-MG, bottom-VI) in stromal, 
osteo-stromal, osteogenic medium for 7, 14 and 21 days respectively Significant 
differences are indicated by *, ** and *** within the same time points among different 
medium and by a, b and c within the same medium type among different time points.   
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A. B.  
C.  D.  
E.  F.   
Figure 27 SEM images of ASCs on all three different scaffolds. 
SEM images of ASCs on all three different scaffold (A. UF only; B. UF with cell; C. MG 
only; D. MG with cell; E. VI only; F. VI with cell) after 7 days culture in osteogenic 
medium, compared with scaffolds only without cells. 
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evaluate their seeding efficiency and osteogenesis potential on three different commercially 
available scaffolds.  Overall, UF and MG were superior to VI in ASCs attachment, growth, 
differentiation and ECM secretion, indicating possible critical role of porous COLI 
components in efficient osteogenesis.  Continuous exposure to osteogenic medium was 
proved to be the best for in vitro osteogenesis especially for ASCs on MG scaffolds.  Short-
term osteogenesis induction was able to trigger osteogenesis process similar to long-term 
osteogenesis after 28 days of culture.  Substantial upregulation of CB1 in osteogenic medium 
demonstrated that cannabinoid pathway may play an important role in differentiation of 
osteoprogenitor cells.  This study established procedures to optimize in vitro customized 
bone regeneration with spinner flasks loading of easy to be isolated human ASCs onto 
suitable commercially available scaffolds.  This achievement significantly investigated the 
great potential of adult ASCs to meet the needs of human bone regeneration.   
Seeding efficiency, viability, DNA contents and ultrastructure of ASCs noticeably differed 
among the scaffolds and showed consistent results with UF as the most suitable scaffolds for 
ASCs adhesion and proliferation. Spinner flasks provided identical environment for ASCs 
loading on all three different scaffolds.  The differences existed among the scaffolds are due 
to their diversity in morphology and composition.  It is possible that decreased capacity for 
cell adhesion and proliferation was caused by increased proportion of ceramics components 
and subsequent decreased porosity from UF to VI.  Both UF and MG have porous structure 
which might favor the cell attachment, migration, proliferation and differentiation of the 
ASCs. Compact and crystal structure of VI may not be in favor of the cell adhesion process. 
This structural difference may be the key factor to the observed difference in scaffolds 
capacity to support cell growth.   
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Although MG had decreased cell adhesion compared with UF, MG is more appropriate for 
osteogenesis with addition of ceramics components without compromising its porous 
structure, indicated by its most enhanced osteogenic gene upregulation and ECM formation.  
ALP expression increased significantly as early as 7 days while significant OCN 
upregulation did not present until 28 days of induction on MG. This is in agreement with 
established concept that ALP is early and OCN is a late osteogenic marker.  In comparison, 
ALP and OCN expression did not show any significant change over time or in different 
medium for VI, indicating the lack of support by VI for ASCs osteogenesis.  The significant 
upregulation of ALP for ASCs on UF after 14 days of induction suggested the role of UF in 
osteinductivity.  ECM formation was consistent with changes of osteogenic gene expression. 
Newly formed ECM was most enhanced on UF in long-term osteoinduction medium.  Long-
term osteoinduction affects significantly for GAG formation on MG.  VI still showed no 
difference by both medium and time for all outcomes. In summary, UF is considered the 
optimal scaffolds for ASCs adhesion and growth while MG is most suitable for osteogenesis 
with minimal compromise to support cell proliferation, indicating MG as the best candidate 
to support ASCs into functional bone specific tissue.  
OPG/RANKL pathway plays an important role in the regulation of osteoclast maturation [25-
27].  Many paracrine factors including cytokines regulate differentiation of osteoclasts by 
regulating RANKL and OPG expression.  The osteogenic effects of BMP2 was confirmed by 
increased OPG/RANKL ratio in human MSCs on calcium phosphate substrate when treated 
with BMP2 at day 12 [197].  OPG/RANKL ratio expressed by ASCs increased significantly 
after 14 days of induction on MG and this increase peaked at day 28 for all scaffolds, which 
indicated that active osteogenesis.  Substantial upregulations of CB1 receptor with ten 
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thousands fold increase on all scaffolds after 14 days induction suggested the important role 
CB1 plays in osteogenesis.  Furthermore, there was consistent significant positive correlation 
between CB1 receptor and OPG/RANKL ratio on all three scaffolds, emphasizing the role of 
CB1 as osteogenesis regulator.  CB2 receptor, though less influential as CB1, showed similar 
increasing trend as CB1 and may share the osteogenesis regulation function.  CB1-/- mice had 
defects in osteoclast formation, which was caused by a decreased sensitivity of osteoclast 
precursors to RANKL as well as no sufficient RANKL expression to support osteoclast 
formation [21].  Bone marrow cells of CB2-/- mice also produce fewer osteoclasts than wild-
type controls in response to RANKL [190]. Therefore with increased expression of CB1 and 
CB2, less RANKL is required to maintain balance between osteoblast and osteoclast 
formation.  This is consistent with negative correlations between RANKL and both CB1 and 
CB2, which is significant on MG scaffolds.  Cannabinoid pathway may play a role in adult 
MSC osteogenesis, especially having impacts on osteoprogenitor cells to switch them from 
self-renewal process to differentiation process. There were still a large proportion of 
progenitor cells existing as early as day 7. With increased expression for CB1 and CB2 
caused by osteoinduction, their self-renewal process was suppressed and osteoprogenitor 
cells started to differentiate. This further triggered the OPG/RANKL pathway to regulate the 
differentiated osteoblast and osteoclast for bone formation.  The correlation between 
OPG/RANKL and CB1/CB2 might suggest that they can provide positive feedback to each 
other.  Further research should be conducted to confirm this preliminary finding.  A further 
study using knockdown technique may be able to establish the exact role of cannabinoid 
receptor in human ASCs osteogenesis.  
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In this study we selected three scaffolds of different composition and structure and 
investigated their suitability for bone regeneration with ASCs. We also intended to test how 
osteogenic potential of ASCs on biocompatible scaffolds is affected by increased proportion 
of osteoinudctive ceramic components.  This study clearly showed the difference in the 
osteoinductive properties of these scaffolds when loaded with ASCs and established MG as 
the optimal scaffolds for osteogenesis of human ASCs.  Osteogenesis was significantly 
enhanced by continuous exposure to osteogenic medium.   Short exposure to osteogenic 
medium did not have any significant effect on osteogenesis although it had a transient effect 
on gene expression, suggesting that short-term exposure to osteogenic media might have an 
osteoinductive effect in vivo.  Further studies are necessary to determine if similar results 
occur in vivo.  One limitation of this study is the difficulty in discerning which properties of 
scaffolds (i.e., composition, surface chemistry, pore structure or porosity) are responsible for 
the observed differences.  Because the scaffolds used in this study had different surface 
topography, porosity, physical characteristics and chemical composition.  Further 
investigation using scaffolds with the same chemical composition but with different surface 
and pore structures may be able to acquire more information on interaction mechanism 
between cell and scaffold.  The present study investigated systematically to solve the current 
issues associated with difficulties in selection of suitable bioscaffolds for bone regeneration 
and offers a basis for future studies involving stem cell-based therapy in order to improve 
bone regeneration process.    
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 CHAPTER 5. THREE-DIMENSIONAL BIOSCAFFOLDS FOR ADULT EQUINE 
MULTIPOTENT STROMAL CELLS OSTEOGENESIS IN VITRO: A 
PRELIMINARY REPORT 
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5.1 Introduction 
Synthetic polymers provide diversity by altering their fabrication parameters.  The 
morphology and porosity as well as the pore size can be modified to match tissue specific 
needs for mechanical properties and rates of degradation. Increase in porosity allows for 
adequate diffusion and it should be adjusted without compromising its mechanical properties.  
Polylactic acids (PLLA) are considered as the most frequently used polymers in bone tissue 
engineering [198-199].  Polyethylene glycol (PEG) is often used to construct copolymer with 
PLLA to adjust the degradation rate [198, 200].  However, the surfaces of polymers are not 
very suitable for cell attachment.  There are other bioscaffolds resemblance to bone inorganic 
components considered as promising candidates for producing bone construct, such as 
hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP).  But the low mechanical strength 
and relatively slow degradation may limit their application in bone regenerations. Therefore, 
it is critical to assess their effects alone as well as their combinations to choose the best 
bioscaffolds for bone regeneration.   
The two most common and easy to access sites for isolating adult equine multipotent stromal 
cells (MSCs) are bone marrow from sternal bone and adipose tissue from superficial gluteal 
muscle [13, 134].  Therefore equine bone marrow- (BMSCs) and adipose derived multipotent 
stromal cells (ASCs) are chosen here to explore their potential application in equine tissue 
regeneration seeded onto bioscaffolds suitable for bone regeneration.  Before applying them 
in equine patient, it is critical to evaluate their osteogenesis efficiency in vitro and thus can 
help to determine the optimal scaffold for later bone regeneration in vivo.    
Another critical factor need to be investigated here is the sufficient time needed for induction 
before implantation.  Cell-scaffold constructs should be pre-induced in osteogenesis 
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microenvironment before implantation to ensure their commitment into osteogenesis lineages.  
The shortest time required for osteogenesis should be determined to ensure the efficiency of 
this procedure.  In this study, BMSCs and ASCs were seeded onto three different 
bioscaffolds composed with polymer alone (PLLA/PEG), polymer with bone-like component 
- ceramics (PLLA/PEG/HA/ β –TCP) and ceramics alone (HA/ β –TCP).  Cell-scaffold 
constructs were then induced for different time points to assess and compare their 
osteogenesis capacity and efficiency in vitro.  
5.2 Materials and Methods 
5.2.1 Experimental Design 
Cryopreserved passage 0 or 1 equine ASC and BMSCs were retrieved and expanded up to 
passage 3 to acquire adequate cell number for all the outcome measurements.  Cells were 
then loaded onto round 60%/40% PLLA/PEG, round 36%/24%/24%/16% PLLA/PEG/ HA/β 
–TCP (generous gifts from Dr Daniel Hayes) and 60% HA/40% β – TCP (Scaffdex, Tampere, 
Finland) by spinner flasks at a loading concentration of 106 cells/per scaffold.  Cell-scaffold 
constructs were evaluated immediately after loading and after 7, 14 and 21 days of culture in 
osteogenic induction media as well as stromal media when scaffolds were assessed for cell 
viability, cell proliferation, cell differentiation, extra cellular matrix synthesis and 
ultrastructures of cell as well as cell-scaffold constructs. 
5.2.2 Animals 
Cells used in this study were isolated from 3 Thoroughbred geldings (7 to 10 years old).  
Bone marrow (BM) was collected from sternebrae and adipose tissue was collected from 
superficial gluteal fascia[13, 134].  The collection procedure was approved by the 
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Institutional Animal Care and Use Committee.  Stromal cell isolations were performed 
immediately after tissue harvest.   
5.2.3 Stromal Cell Isolation and Cryopreservation 
The BM aspirate was diluted 1:1 with DMEM-Ham’s F12 (Hyclone, Logan, UT) with 1% 
antibiotic/antimycotic solution (MP Biomedical, Irvine, CA) and 10% characterized fetal 
bovine serum (FBS, Hyclone, Logan, UT) added.  It was then layered over Ficoll-Paque 
PLUS (Stem Cell Technologies) and centrifuged (350 g, 30 min).  The total nucleated cell 
numbers per unit volume of BM aspirate were then calculated from BMSC - enriched layer. 
Adipose tissue was minced in a sterile petri dish, washed and briefly agitated with an equal 
volume of phosphate buffered saline (PBS) to promote separation into two phases.  The 
upper phase containing hematopoietic cells was removed.  The tissue was then digested in an 
equal volume of a filtered (0.2 µm) PBS solution containing 1% bovine serum albumin type 
V (BSA) (Sigma, St Louis, MO) and 0.1% collagenase type I (Worthington, Lakewood, NJ).  
The tissue and solution were continuously rotated at 370C for 30 minutes with brief agitation 
every 15 minutes.  Subsequently, the sample was centrifuged (350g, 5 min).  To complete 
stromal cell separation from primary adipocytes, the sample was briefly and vigorously 
agitated and then centrifuged (350g, 5 min) resulting in a stromal-vascular fraction (SVF) 
pellet.  The SVF pellet was resuspended in 2 ml of stromal media.  A small aliquot of the cell 
suspension was centrifuged and resuspended in an equal volume of red cell lysis buffer for 5 
minutes.  The total nucleated cell numbers per unit volume of adipose tissue were then 
calculated. 
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The fresh isolated cells were cultured for 4 -5 days.  Cells were passaged once if there were 
no sufficient cell number from passage 0.  Then aliquots of cells (1 x 106 cells/ml) of passage 
0 or 1 were frozen in cryopreservation medium, which was made up with 80% FBS, 10% 
DMEM, and 10% dimethylsulfoxide.  
5.2.4 Flow Cytometry 
Revitalized BMSCs and ASCs were cultured for 4-5 days until 70% confluence.  Cells from 
3 equine donors were pooled equally and cells (2 x 105) were suspended in 150 ul PBS and 
then mixed with 1.5 mL PE conjugated CD 34, CD29，CD73 and FIFC conjugated CD 
44,CD45, CD90 and CD105 (Table 1) in 5 ml round bottom glass tubes and incubated for 30 
minutes in room temperature.  Cell aliquots served as the autofluorescence controls.  Samples 
were rinsed with 2 ml PBS followed by centrifugation (350g, 5 minute).  The cell pellet was 
fixed in 30 ul of cold 1% formalin and stored at 4oC until FACS Analysis.  
5.2.5 Cell Seeding 
Revitalized passage 0 or passage 1 ASCs and BMSCs were expanded up to passage 3 in 
stromal medium (DMEM-Ham’s F12 (Hyclone, Logan, UT), 1% antibiotic/antimycotic 
solution (MP Biomedical, Irvine, CA), and 10% characterized fetal bovine serum (FBS, 
Hyclone, Logan, UT)).  Seeding density was 5,000 cells/cm2 for all passages and cells were 
passaged at 70-80% confluence.  Passage 3 cells from 3 equine donors in stromal media were 
pooled and loaded onto 3 different scaffolds in spinner flasks.  Loading was performed for 
two hours in a humidified incubator (37º C, 5% CO2). 
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5.2.6 Cell Proliferation 
Cell proliferation was analyzed using [3-(4,5-dimethylthiazol-2-yl)-1, 5-diphenyl tetrazulium 
bromide] (MTT, Sigma, USA) mitochondrial reaction.  This assay is based on the ability of 
live cells to reduce a tetrazulium-based compound, MTT, to a purplish formazan product. 
Briefly, cells/scaffold constructs either from day 0, 7 or 21 days of 3D culture were first 
washed with PBS, transferred into new 24-well plates containing a 5:1 ratio of media and 
MTT solution (5 mg/mL in PBS) respectively and incubated for 2h at 37ºC. After removing 
the culture media, 0.5mL of extraction solution (DMSO) was added. The constructs were 
washed extensively by pipetting up and down repeatedly to allow total color release. The 
absorbance of the supernatant was read with a microplate reader (BioTek, USA) at 540 nm. 
The cell number on scaffolds was determined via a standard curve that was established using 
a known number of cells counted by hemocytometer using light microscope. 
5.2.7 Alkaline Phosphotase Staining for Osteogenesis 
Osteogenesis was demonstrated by comparing the amount of staining on the composite 
scaffolds using an alkaline phosphotase (ALP) staining (Chemicon, USA).  Constructs were 
washed in PBS and fixed in 10% formaldehyde for 1 hour at room temperature.  ASMX and 
fast red stock solution was made by dissolving them respectively in distilled water with 50 
mg/ml concentration.  Then ASMX and fast red stock solutions were mixed and diluted in 
PBS to 1/200 and 1/400 respectively to make ALP staining solution.  After washing three 
times with PBS, the constructs were incubated in ALP staining solutions for few hours.  
Scaffolds without cells were used as a control. 
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5.2.8 Scanning Electron Microscopy 
Cell-scaffold constructs cultured in osteogenic medium were evaluated with SEM after 7 and 
21 days of culture.  Constructs were fixed in 2% paraformaldahyde and 1.25% 
glutaraldehyde in 0.1 M sodium cacodylate (CAC) buffer, pH 7.4.  Samples were rinsed in 
0.1M CAC buffer with 5% sucrose and incubated with 1% osmium tetroxide in 0.1 M CAC 
buffer.  They were dehydrated in a series of ethanol-distilled water solutions, critical point 
dried in a Polaron CO2 bomb, and then sputter coated with gold and palladium. Samples were 
imaged with a scanning electron microscope (Quanta 200, FEI Company, Hillsboro, OR) at 
15 kVP.  
5.2.9 Transmission Electron Microscopy 
Transmission electron microscopy was performed as described previously (Shakibaei et al, 
1997).  Cells cultured with scaffolds in osteogenic medium were trypsinized, centrifuged and 
washed in PBS. After the second centrifugation, cell pellets were fixed in 2% 
paraformaldahyde and 1.25% glutaraldehyde in 0.1 M sodium cacodylate (CAC) buffer, pH 
7.4.  Samples were rinsed in 0.1M CAC buffer with 5% sucrose and incubated with 1% 
osmium tetroxide in 0.1 M CAC buffer. The cell pellets were dehydrated in a series of 
ethanol-distilled water solutions and embedded in Epon (Plano, Marbug, FRG). Ultrathin 
sections of the constructs were prepared and evaluated with a transmission electron 
microscope (TEM).   
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5.3 Results 
5.3.1 Flow Cytometry 
Stromal cell surface marker expression was higher in BMSCs for four out of five of those 
investigated in this study.  Specifically, 90.30% of BMSCs and 98.98 % of ASCs were 
CD29+; 1.47% of BMSCs and 10.97% of ASCs were CD44+; None of BMSCs and ASCs 
were CD73+; 28.19% of BMSCs and 46.24% of ASCs were CD90+; and 58.83% of BMSCs 
and 87.23% of ASCs were CD105+.  Both BMSCs and ASCs were negative for CD34 (Fig. 
28).   
 
Figure 28 Histogram of flow cytometry results.   
Histogram of CD 29, CD44, CD73, CD90, and CD105 antibody stained cell (black) with 
auto fluorescent control cell (green) for both BMSCs and ASCs. 
5.3.2 Cell Proliferation 
Overall, there were no significant differences between ASCs and BMSCs based on cell 
metabolic activity.  Metabolic activity was affected significantly by time on all three 
scaffolds for BMSCs and on HA/β-TCP scaffold for ASCs. For BMSCs on all three scaffolds 
and ASCS on HA/β-TCP, their metabolic activities were significantly higher at day 21 
compared with day 7 (Fig. 29).  
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Figure 29 MTT assay to quantify cell metabolic activities on all three scaffolds. 
Mean±SD of fold change of cell metabolic activity of both BMSCs and ASCs on 
PLLA/PEG, PLLA/PEG/HA/TCP and HA/TCP scaffolds after 0, 7 and 21 days of 
culture in osteogenic medium. Different letters indicated significant differences between 
different culture time within the same cell type.  
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5.3.3 ALP Staining for Osteogenesis 
For both ASC and BMSC on all three scaffolds, there were distinct differences of ALP stain 
between non-induced and osteogenic induced group at their outer surfaces (Fig. 30 and 31).  
Between constructs induced for 7 and 21 days, however, there were no apparent differences 
of the stain at both outer surfaces and inner surfaces (Fig. 30-33).  Compared between outer 
surfaces and inner surfaces, it was obvious that much less stain existed on the inner surfaces 
than outer surfaces for all the stained groups especially for cell-HA/β-TCP constructs (Fig. 
30-33).   
 
Figure 30 ALP stained the outer surfaces of all three ASCs–scaffolds constructs under 
osteogenic induction for 7 and 21 days as well as under no induction at time 0 as control.    
ALP stained the outer surfaces of ASCs-PLLA/PEG constructs (A-C), ASCs-
PLLA/PEG/HA/β-TCP constructs (D-F), and ASCs-HA/β-TCP constructs (G-I) under 
osteogenic induction for 7 days (B, E, H) and 21 days (C, F, I) as well under no 
induction at time 0 as control (A, D, G).  
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Figure 31 ALP stained the outer surfaces of all three BMSCs–scaffolds constructs 
under osteogenic induction for 7 and 21 days as well as under no induction at time 0 as 
control.    
ALP stained the outer surfaces of BMSCs-PLLA/PEG constructs (A-C), BMSCs-
PLLA/PEG/HA/β-TCP constructs (D-F), and BMSCs-HA/β-TCP constructs (G-I) 
under osteogenic induction for 7 days (B, E, H) and 21 days (C, F, I) as well under no 
induction at time 0 as control (A, D, G).  
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Figure 32 ALP stained the inner surfaces of all three ASCs–scaffolds constructs under 
osteogenic induction for 7 and 21 days as well as under no induction at time 0 as control.    
ALP stained the inner surface of ASCs-PLLA/PEG constructs (A-C), ASCs-
PLLA/PEG/HA/β-TCP constructs (D-F), and ASCs-HA/β-TCP constructs (G-I) under 
osteogenic induction for 7 days (B, E, H) and 21 days (C, F, I) as well under no 
induction at time 0 as control (A, D, G).  
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Figure 33 ALP stained the inner surfaces of all three BMSCs–scaffolds constructs 
under osteogenic induction for 7 and 21 days as well as under no induction at time 0 as 
control. 
ALP stained the inner surface of BMSCs-PLLA/PEG constructs (A-C), BMSCs-
PLLA/PEG/HA/β-TCP constructs (D-F), and BMSCs-HA/β-TCP constructs (G-I) 
under osteogenic induction for 7 days (B, E, H) and 21 days (C, F, I) as well under no 
induction at time 0 as control (A, D, G).  
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5.3.4 Scanning Electron Microscopy 
Three scaffolds demonstrated distinct ultra-structures visualized by SEM (Fig. 34).  
Compared with PLLA/PEG scaffolds, PLLA/PEG/HA/β-TCP scaffolds had much more 
organized pore structures. HA/β-TCP scaffolds were composed with much lower porosity 
and the macro-pores were much larger than the other scaffolds (Fig. 34A-C). However, after 
examined with higher magnification, the micro-pores of HA/β-TCP scaffolds were much 
smaller than the other two scaffolds. HA/ β-TCP scaffolds were mainly composed by dense 
mineral granules while the other two scaffolds demonstrated fibrous and membranous 
structure.  It was shown that the white and bright spots accumulated randomly were the 
mineral components of PLLA/PEG/HA/β-TCP scaffolds (Fig. 34E).   
 
Figure 34 SEM image demonstrated the ultrastructure of all three scaffolds at 400x and 
3000x magnification.  
SEM images of PLLA/PEG scaffold (A), PLLA/PEG/HA/β-TCP (B) and HA/β-TCP (C) 
under the same magnification (400x) as well PLLA/PEG scaffold (D), 
PLLA/PEG/HA/β-TCP (E) and HA/β-TCP (F) under the same magnification (3000x) 
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Because PLLA/PEG and PLLA/PEG/HA/β-TCP scaffolds were fibrous and membranous 
especially did not have organizable pattern at higher magnification, it was very difficult to 
differentiate cell shape and distributions on these two scaffolds (Figure not shown). For 
utrastructure of cell-HA/β-TCP constructs,  polygonal shaped cells were evident on both 
constructs after 7 days of osteogenic induction while ASC-HA/β-TCP constructs generated 
significantly more extra-cellular matrix (Fig. 35 A&D).  The extra cellular matrix were 
matured and expanded to combine with scaffold, which were distinguishable by its distinct 
ultrastructure for ASC-HA/β-TCP constructs cultured for 21 days (Fig. 35E).         
 
Figure 35 SEM image of both ASC- and BMSC- HA/β-TCP scaffolds constructs at 
3000x magnification. 
SEM image of ASCs - (A, B) and BMSCs - HA/β-TCP constructs (D,E) after 7 days 
(A,D) and 21 days (B,E).  HA/TCP scaffold without cells is provided for comparison (C, 
F). Red arrows point to polygonal cells (A, D, E) attached to the scaffold and neo 
extracellular matrix (B).  
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5.3.5 Transmission Electron Microscopy 
Preliminary results of TEM were reported here. ASCs at day 0 without any induction was a 
round cell containing well-developed organelles, mainly composed of large quantities of 
mitochondria, endoplasmic reticulum, lipid droplets, and few ribosomes in cytoplasm. ASC 
was observed with two set of euchromatin in its notched nucleus, which was filled with 
prominent nucleoli. Cell processes were present at the ASCs surface. All these characteristics 
indicated a very active cell metabolism (Fig. 36A).  Compared with ASC without any 
induction, induced ASC for 14 days revealed a distinct difference with larger lipid droplets 
and less structured cell organelles.  Cell did not have processes at the surface. Although the 
size of cell was bigger than ASC at day 0, the euchromatin was much smaller (Fig. 36B).  
 
Figure 36 TEM demonstration of ASCs after day 0 (A) and day 14 (B) of osteogenic 
induction.  
TEM demonstration of ASC without any induction (A) and ASCs under 14 days of 
osteogenic induction (1- nucleus, 2-mitochondria, 3- endoplasmic reticulum, 4-a lipid 
droplet, 5-a ribosome, 6-euchromatin) 
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ASCs on three scaffolds after 14 days of induction did not reveal any substantial differences 
between each other as well as compared with ASCs control. ASC on PLLA/PEG/HA/β-TCP, 
however, contained much larger quantities of lipid droplets. On the contrary, ASC on HA/β-
TCP contained the least amount of lipid droplets. ASCs of all groups contained a number of 
mitochondria, a sign for active cell metabolism (Fig. 37).        
 
Figure 37 TEM demonstration of ASC constructs of all three scaffolds as well as ASCs 
only as control after 14 days of osteogenic induction.  
TEM demonstration of ASC constructs of all three scaffolds (A. PLLA/PEG, B. 
PLLA/PEG/HA/β-TCP, C. HA/β-TCP) as well as ASCs only as control after 14 days of 
osteogenic induction. 
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5.4 Discussion 
This pilot study demonstrated the osteogenic lineage differentiation potential of both equine 
BMSCs and ASCs in vitro on three bioscaffolds suitable for bone regeneration.  It was 
preliminarily confirmed that all three scaffolds are suitable for cell adhesion, proliferation 
and differentiation into functional osteo-specific tissue during in vitro development.   
The pooled BMSCs and ASCs showed similar immunophenotype and had positive 
expressions for three mesenchymal stromal cell markers. ALP staining solved the difficulties 
that researchers encountered when referred to histology to confirm cell differentiation. 
Because of the fragile structure of polymers and hardness of ceramics, it was very difficult to 
obtain intact pieces of constructs on slides to investigate their microstructure. ALP staining 
of the whole constructs not only avoided unsuccessful sectioning but also provided three-
dimensional view to demonstrate cell distribution on the scaffolds.  It was confirmed by ALP 
staining that both cells can committee osteogenic differentiaton on all three bioscaffolds 
under appropriate induction as early as day 7, which did not reveal dissimilarities from 
differentiation at day 21. Moreover, much less stain on the inner surface of HA/β-TCP 
scaffold for both cell types indicated the insufficient cell migration into the scaffolds that 
may be caused by its lack of micro-pores.  The fact that cell metabolic activities was 
significantly increased at day 21 compared with day 7 for all BMSC constructs and for ASC-
HA/ β-TCP constructs may suggest that parts of cells at day 7 still maintain its ability of self-
renewal.   
The ultrastructure of all three scaffolds revealed the advantages of polymer components of 
scaffolds, which showed interconnected pore structures suitable for cell attachment.  
However, the dense structure composed by HA may indicate better mechanical properties.   
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The polygonal shaped cells existed for both cell-HA/β-TCP constructs with more developed 
extra cellular structure on ASC constructs. This indicated that compromised pore structures 
of HA/β-TCP did not cause insufficient cell adhesion onto the surface of this scaffolds.  
Moreover, this scaffolds provided excellent support for extra cellular matrix formation.  
However, there were no recognizable SEM images to demonstrate cell adhesion and extra 
cellular matrix formation on the other two scaffolds due to their structures.  
In order to examine and compare cell progression into osteogenic lineages among all three 
scaffolds, TEM was introduced to compensate the incomplete results from SEM.  Due to few 
technique issues, this preliminary study only included ASCs on all three scaffolds after 14 
days of induction.  Overall, it was obvious that ASCs under induction on all three scaffolds 
showed distinct cellular structure compared with ASCs without any induction.  Besides, the 
differences existed among different constructs, which need further investigation to reveal the 
underlying mechanism.  
In conclusion, these preliminary data has demonstrated, for the first time, that equine ASCs 
and BMSCs posses osteogenic potential when loaded onto bioscaffolds under induction.  The 
displayed ultrastructure of cell on bioscaffolds further supported this finding. A 
comprehensive study with a deeper insight into the osteogenic differentiaton mechanism may 
help to uncover the interactions between cell and scaffolds and therefore promote the future 
use of equine MSCs in equine regeneration medicine, which may contribute to customized 
biomaterials to match different clinical needs 
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CHAPTER 6. CONCLUSIONS AND FUTURE RESEARCH 
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The major contribution of these studies is that they established straightforward and 
reproducible procedures to support customized tissue engineering with proper bioreactors 
loading of easy to be isolated adult MSCs onto suitable bioscaffolds to grow aimed tissue 
type.  The results showed that the suitability of bioscaffolds for MSC growth can be 
confirmed by high MSC viability and increased DNA contents over time.  Furthermore, cell 
differentiation capacity into distinct mesenchymal tissues on bioscaffolds was successfully 
quantified by related mRNA upregulation and ECM formation.  Therefore the optimization 
of cell-scaffold constructs can be achieved to ensure their high efficiency to commit to 
specific tissue lineages.  These achievements expanded the application of equine regenerative 
medicine.  Using proper engraftments of cells on bioscaffolds can expand application of 
equine stem cell therapy, which was previously limited to MSCs administration as a single 
product.  MSCs integration into lesion sites guided by bioscaffolds as a tissue graft will 
significantly increase the efficiency of healing in clinics in near future.   
It was shown by the first in vitro study that both equine BMSCs and ASCs demonstrated 
good cell adhesion and growth on COLI scaffolds. According to the requirement of current 
stem cell therapy, at least 10 million cells are needed for one injection to repair lesions.  To 
obtain this amount of cells, it normally takes 3-4 weeks’ culture.  One reason of doing this 
time-consuming cell culture is because of the fewer cells stayed at lesion sites due to cell 
migrations. Scaffolds play an important role in maintaining sufficient cells on the lesion sites 
for tissue repair. The potential of COLI scaffolds in targeting majority of cells to treat 
injuries in vivo was established by their strong capacity to support cell adhesion and growth 
in vitro. Therefore cell migration can be suppressed and much fewer cells are needed, which 
will shorten the culture time and improve the efficiency of stem cell therapy. Time is 
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important when considering the clinical applications especially for acute injury cases.   
Furthermore, multipotentiality of equine MSCs was supported on COLI scaffolds, which 
accomplished the first critical step to provide comprehensive results to evaluate cell-scaffold 
interactions and establish their potential in multiple tissue repairs.  In summary, this study 
presented important information on how to design engineered tissue and stepped forward 
towards the long-term goal of meeting diverse clinical needs in equine tissue regeneration.  
The developed cell adhesion, growth and induction behavior on COLI scaffolds was further 
applied in vivo using nude mice to investigate their potential in equine tissue regeneration. 
BMSC-COLI constructs under short-term induction produced bone formation 3 weeks after 
subcutaneous implantation while ASCs-COLI constructs required additional induction to 
committee osteogenesis in vivo.  This will accelerate applications of engineered bone-
forming constructs using BMSCs to expedite equine bone repair in near future.  ASC 
constructs produced comparative ECM as that of BMSC constructs but under commitment 
into dermal-like tissue, indicating ASCs more responsive to signal cues encountered 
subcutaneously due to their original niches.  Considering the key advantages of ASCs with 
high harvest rate, easy to isolate and minimal injury to donor site, pre-induction time and 
scaffolds components were further optimized in vitro to improve efficiency of ASCs 
constructs to commit osteogenesis.    
Scaffolds component and porous structure were further confirmed as the two major factors 
that influence the ability of human ASCs to commit osteogenesis.  Compared with COLI 
scaffolds, MG scaffolds added osteoinductive ceramics components while still maintaining 
similar porous structure.  This study established MG as the optimal scaffolds for supporting 
osteogenesis of human ASCs without compromising its ability to maintain good cell 
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adhesion and high cell growth rate.  Furthermore, osteogenesis was significantly enhanced by 
continuous exposure to osteogenic medium. By exploring the molecular mechanism of 
osteogenesis of cell-scaffold constructs, this study preliminarily demonstrated that 
cannabinoid pathway may play an important role in differentiation of osteoprogenitor cells.  
This accomplishment established the important role of human ASCs in osteogenesis under 
optimized conditions.  Further studies are necessary to determine if similar results occur in 
vivo.   
Our research solved the current dilemma of lack of solid-evidence based studies to support 
clinical use of MSCs in equine regenerative medicine.  These studies investigated the 
mechanism of how MSCs function to restore tissue architecture and function and will 
improve the efficiency of stem cell therapy by introducing proper engraftment of MSCs 
through efficient bioreactor loading onto suitable bioscaffolds.  The improved understanding 
of MSCs behaviors on bioscaffolds to commit to specific tissue regeneration especially bone 
regeneration should guide development of future regenerative therapies to address specific 
equine patients need in clinics.       
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